



GIRL, DISRUPTED



Hormone Disruptors and Women's Reproductive Health

*A REPORT ON THE WOMEN'S
REPRODUCTIVE HEALTH AND
THE ENVIRONMENT WORKSHOP*



Girl,

This report was produced by the Collaborative on Health and the Environment (CHE). CHE's administrative headquarters are located at Commonweal, a health and environmental research institute in Bolinas, California.

For copies of this report or for more information, please contact:

CHE / Commonweal
PO Box 316, Bolinas, CA 94924
Phone: 415-868-0970 • Fax: 415-868-2230
Email: info@healthandenvironment.org
Web: www.healthandenvironment.org

January 2009

Design by half-full (www.half-full.org)

Printed with soy-based ink on New Leaf Reincarnation paper (100% recycled, 50% post-consumer content, processed chlorine free).



Disrupted

Hormone Disruptors and Women's Reproductive Health

A Report on the Women's Reproductive Health and the Environment Workshop

This report summarizes the key outcomes of the Women's Reproductive Health and the Environment Workshop, held in January 2008 at Commonweal, a health and environmental research institute in Bolinas, California. The scientific results of the workshop were written by Crain et al. and are published in "Female reproductive disorders: The roles of endocrine disrupting compounds and developmental timing." The article can be found online at www.fertstert.org in the October 2008 issue of the journal *Fertility and Sterility*.¹ See References for full citation.

The workshop was convened by the Collaborative on Health and the Environment (CHE), in partnership with the University of Florida (UF) and the University of California, San Francisco's Program on Reproductive Health and the Environment (PRHE). This event was co-chaired by Dr. Louis J. Guillette Jr. at UF (www.zoology.ufl.edu/ljg) and Dr. Linda

Giudice at PRHE (www.prhe.ucsf.edu). Please contact these individuals for further information about this research.

Funding for this project was provided by:

- John Burbank and Alison Carlson
- Barbara Smith Fund
- Johnson Family Foundation
- The New York Community Trust
- Turner Foundation, Inc.

Thank you for your financial support and contributions to this project.

For more information about the workshop, please visit: www.healthandenvironment.org/reprohealthworkshop.



Acknowledgments

Authors

Julia Barrett, Freelance Science Writer and Editor in the Life Sciences

Shelby Gonzalez, Administrative Coordinator, Collaborative on Health and the Environment

Heather Sarantis, MS, Women's Health Program Manager, Commonweal

Julia Varshavsky, Program Associate and Coordinator of the Fertility/Reproductive Health Working Group, Collaborative on Health and the Environment

Special thanks

Thea Edwards, PhD, Post-Doctoral Associate in the Department of Zoology at the University of Florida for contributing to this report.

Reviewers

Charlotte Brody, RN, Director of Programs, Green For All

Alison Carlson, Founder and Advisor, Fertility/Reproductive Health Working Group, Collaborative on Health and the Environment; and Senior Advisor on Environmental Health, Passport Foundation

D. Andrew Crain, PhD, Associate Professor of Biology, Maryville College

Linda C. Giudice, MD, PhD, MSc, Professor and Chair, Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco; and **The Robert B. Jaffe**, MD, Endowed Professor in the Reproductive Sciences, University of California, San Francisco

Louis J. Guillette Jr., PhD, Distinguished Professor, Department of Zoology, University of Florida, Gainesville; and Professor, Howard Hughes Medical Institute, University of Florida

Patricia Hunt, PhD, Meyer Distinguished Professor, School of Molecular Biosciences, Washington State University

Sarah Janssen, MD, PhD, MPH, Staff Scientist, Natural Resources Defense Council

Mary Tyler Johnson, MPA, MPH, Project Advisor and Environmental Health Consultant

Eleni Sotos, MA, Environmental Health Consultant

Teresa K. Woodruff, PhD, Thomas J. Watkins Professor of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University; and Executive Director, Institute for Women's Health Research

Tracey J. Woodruff, PhD, MPH, Associate Professor and Director, Program on Reproductive Health and the Environment, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco; and Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco

Contents

Introduction ■ 6

The Problem ■ 6

Building Consensus: The Women's Reproductive Health and the Environment Workshop 6

The Basics ■ 7

Are Female Reproductive Disorders on the Rise? 7

What Role Do Hormones Play? 8

Hormones, Disrupted 9

How We Are Exposed 10

Getting Perspective: The Historical Context ■ 11

The Myth of the Impermeable Placenta 11

What Can We Learn from Alligators? 11

Tragic Lessons: Fetal Origins of Adult Disease 13

Scientific Evolution ■ 13

BPA, A Modern Day Human Health Threat: Lessons Learned from DES? 14

"Safe" Levels of Exposure: Not So Safe After All 14

A Toxic Legacy: Multigenerational Effects 15

Timing Matters: Exposure During Critical Stages of Development 16

Development, Disrupted ■ 17

A Brief Look at Female Reproductive Development 17

Reproductive Health Concerns of Women and Girls 18

Early Puberty, 18

Impaired Fertility/Infertility, 18

Abnormal Number of Chromosomes (Aneuploidy), 19

Miscarriage, Preeclampsia, Intrauterine Growth Restriction (IUGR), and Preterm Delivery, 19

Menstrual Irregularities, 20

Polycystic Ovarian Syndrome (PCOS), 20

Multi-oocyte Follicles (MOFs), 21

Uterine Fibroids, 21

Endometriosis, 22

Shortened Lactation, 22

Breast Cancer, 23

Early Menopause (Premature Ovarian Failure, POF), 23

Tangled Links 23

Summary Table of Female Reproductive Health Concerns and Links to Hormone Disruptors 24

Answers, Questions, and the Future ■ 25

What We Have Learned 25

Where Do We Go from Here? 26

Key Resources for Further Information on Female Reproductive Health and the Environment ■ 27

References ■ 28

Introduction

Imagine you are building a house. What would happen if you left a brick out of the foundation, or added a few bricks where they did not belong? The house may seem fine, but the hidden fault might impair the structure or make the house more vulnerable to other stressors. The house may stand for years without trouble, slowly crumble over time, or suddenly collapse in an earthquake or hurricane. Like bricks in

the foundation of a house, hormone-controlled prenatal (before birth) development of the reproductive system lays the foundation for a person's lifelong reproductive health. Small hormone disruptions during this critical time—or at another hormone-driven stage of development like early life or puberty—can lead to reproductive health problems or an increased vulnerability to reproductive disorders later in life.

The Problem

Chemicals can impact female reproductive health by interfering with hormones that regulate reproductive system development.

A woman's body goes through a wide range of changes throughout her lifetime. Each stage of her life, from fetal development through her post-menopause years, involves a direct relationship between her hormones and how her body develops and functions. When this relationship is in balance, it helps create the conditions for good health. When this relationship is out of balance, it can lead to a range of health problems that can be painful and devastating.

Scientific evidence increasingly shows that some industrial chemicals, known as endocrine-disrupting compounds (EDCs), or **hormone disruptors**, can throw off this balance, particularly if exposure occurs during fetal development. Other stages of rapid development are also vulnerable to hormone disruption. With exposure, women and girls are at greater risk for developing reproductive health problems such as early puberty, infertility, and breast cancer.¹

Hormone disruptors have come under increased scrutiny as industrial chemical production has proliferated. Over the last 70 years, more than 80,000 chemicals have been registered for use in commerce. More than 3,000 of these are produced or imported in amounts over one million pounds per year. An EPA analysis finds that 43 percent of these high production chemicals have no testing data on basic toxicity, and only seven percent have a full set of basic test

data.² Many of these chemicals may not harm human health, but without testing we have no way to know. Additionally, a significant number of compounds already tested are now believed to increase risk for serious health problems, and these health problems can be passed on from generation to generation. Although many different chemicals can increase a woman's risk for health problems, hormone disruptors are of particular concern because they can alter the critical hormonal balances required for proper health and development at all stages of a woman's life.

Building Consensus: The Women's Reproductive Health and the Environment Workshop

Historically, most hormone disruptor research has focused on males. Compelled by reports of declining sperm counts, increased incidence of male birth defects, and rising rates of adult testicular cancer, leading researchers gathered in Copenhagen in 1996 to discuss and debate the state of the science on male reproductive health and the environment. The group concluded that hormone disruptors might be contributing to rising rates of male reproductive health problems.³

The meeting also led to the development of the “testicular dysgenesis syndrome” hypothesis, which states that hormone disruption during a key period of fetal testis development might be a common origin for multiple male reproductive disorders. These findings have since stimulated a new generation of research and increased the dialogue around hormone disruptors and male reproductive health among governments, healthcare providers, and the public.¹

What is the state of the scientific evidence on hormone disruptors and women’s reproductive health? In January 2008, 18 leading researchers specializing in issues related to hormone disruption and women’s reproductive health convened at Commonweal, a nonprofit health and environmental research institute in Bolinas, California, to address this question. They agreed on five main activities, including:

1. **Mapping what is known** about female reproductive health problems.
2. **Evaluating the possible role of hormone disruptors** in female reproductive health disorders.
3. **Summarizing critical gaps in research** that prevent us from fully understanding the contributions of hormone disruptors to female reproductive health problems.

4. **Identifying a common origin of female reproductive health problems** in prenatal development, similar to the testicular dysgenesis syndrome hypothesis for males.

5. **Writing a scientific review paper** summarizing their findings, and disseminating the information to a broader audience.

Like the influential paper from the male reproductive health and the environment meeting, the resulting scientific review paper from the women’s environmental reproductive health workshop was published in a respected journal. The review was written by Crain et al. and is titled “Female reproductive disorders: The roles of endocrine-disrupting compounds and developmental timing.” It can be found online at www.fertstert.org in the October 2008 issue of *Fertility and Sterility*.¹ The authors of the paper hope their findings and analysis will catalyze a new wave of research on hormone disruptors and, ultimately, lead to greater protections from chemicals that affect the reproductive health of women and girls. The goal of this report is to translate the complex research findings from the scientific paper for key stakeholders and advocates working to support these same efforts.

The Basics

Before we examine the relationship between hormone disruptors and women’s reproductive health and development, we should consider some basic but important questions and concerns.

Are Female Reproductive Disorders on the Rise?

Do women today suffer a higher rate of reproductive problems than their grandmothers did? It is difficult to know for certain. Historical data and on-going records that could definitively indicate a trend generally do not exist. But the limited data we do have is troubling. Conception rates fell by 44 percent in the United States between 1960 and 2002,⁴ and the number of couples reporting fertility problems has increased over the last two decades. Some of the increase is likely due to people starting families later in life—we know that fertility decreases with age.

But that does not explain why the sharpest increase in reported infertility was seen in younger women, under age 25.⁵⁻⁷

Improvements in health tracking are vital for better understanding female reproductive health trends. We do know that millions of women are affected by reproductive disorders, including early puberty, uterine fibroids, endometriosis, polycystic ovarian syndrome (PCOS), and breast cancer.¹ These health problems can be devastating to a woman’s fertility, overall health and quality of life. In the United States alone, women’s reproductive health disorders cost billions of dollars in healthcare and loss of productivity. Many




FIGURE 1: Major female endocrine tissues, organs, and glands, in purple (partial listing).

factors play a role in a woman's overall reproductive health, including her genetic makeup, diet, age, exercise habits, racial and economic injustices, sexually transmitted diseases, and access to good healthcare. Emerging science shows that hormone disruptors also play a role.

Estrogens are typically considered “female” hormones, and androgens such as testosterone are typically considered “male” hormones, but both estrogens and androgens are present—and needed—to varying degrees in both sexes.

What Role Do Hormones Play?

In order to understand how hormone disruptors impact female reproductive health, it is important to recognize what hormones do. Hormones are important signaling molecules that help different parts of the body communicate. Examples of hormones include adrenaline, estrogen, insulin, thyroid hormones, and testosterone.

The endocrine system consists of an integrated set of organs that use tiny amounts of these hormones to orchestrate the growth, development, and everyday functioning of several of the body's systems, including the entire reproductive system. Endocrine tissues—including the ovaries (women), testes (men), pituitary, thyroid, adrenal glands, and pancreas—secrete hormones into the blood as chemical messengers that direct communication and coordination among the body's tissues. For example,

hormones work with the nervous system, reproductive system, kidneys, gut, liver, and fat to help maintain and control several functions, including:

- Body energy levels
- Reproduction
- Growth and development
- Internal balance of body systems (called homeostasis)
- Responses to surroundings, stress, and injury⁸

It is a complex balancing act. Endocrine tissues are like air traffic control towers at busy airports.

One way that hormones convey messages is by connecting with specific receptors that exist on a cell surface or within a cell. When they connect to their receptor, a cellular response follows. Often this includes a particular gene being turned on or off. In

order for a gene to be “read,” the DNA uncoils so the “text” of the gene can be ultimately translated into a protein. Proteins comprise much of our body’s structures, govern chemical reactions in our cells, keep our metabolic machinery ticking, and regulate our immune response. The uniqueness of each person’s genetic code means that people also differ in their protein makeup. This is one reason why two people might respond differently to the same hormone disruptor.

Hormones, Disrupted

Hormone disruptors are substances that interfere with the production, release, transport, metabolism, binding, action, or elimination of the body’s natural hormones. Usually, hormones bind to their receptors like a lock and key. When the hormonal key fits the




FIGURE 2: A depiction of how hormones connect with specific receptors on a cell surface or within a cell. A cascade of cellular events follows that often results in a particular gene being turned on or off. Hormone disruptors can interfere with this process.

How We Are Exposed

People can be exposed to hormone disruptors indoors and outdoors, at home, in daycare or school, and in the work-place. Hormone disruptors get into our bodies when we breathe, eat, drink, and have skin contact with them. They can be found in household products such as cosmetics, food containers, and toys. They can come from industrial pollution and cigarette smoke. Many pesticides are hormone disruptors and can end up on our food and in our drinking water. The below table provides a few examples of hormone disruptors and their sources, but more research is needed to identify all hormone disruptors and their potential health impacts.

Table 1: Examples of Hormone Disruptors

Atrazine	One of the most heavily used herbicides in the United States and widely applied to lawns, corn, and soy crops. It is banned in the European Union due to concerns of groundwater contamination. ⁹
Bisphenol A (BPA)	Invented as a synthetic estrogen in 1936 and was considered for use in pharmaceuticals ¹⁰ until the more potent estrogen, diethylstilbestrol (DES), was synthesized in 1938. ¹¹ Thus, BPA was never used as a drug. Instead, since 1957, BPA has been used to make many common products, including some plastic products such as sports bottles and baby bottles, and in the linings of cans for food and infant formula.
Cigarette Smoke <i>First and Secondhand</i>	Contains hundreds of chemicals, including some hormone disruptors. More research is needed to fully understand how cigarette smoke affects hormone function. This research is especially important because cigarette smoke is very common and because so many health problems are associated with it.
Dichloro diphenyl trichloroethane (DDT)	This insecticide was widely used in the United States until it was banned in 1972 due to toxicity. ¹² DDE, a by-product from the breakdown of DDT is also harmful. DDT is still used in some other countries, often to eliminate mosquitoes associated with malaria risk.
Diethylstilbestrol (DES)	A synthetic estrogen that was first synthesized in 1938 ¹¹ and was mistakenly thought to prevent miscarriages. The drug was prescribed until the early 1970s, when its associated health risks became known. We have learned a lot about how hormone disruptors work by studying the daughters of women who took DES during pregnancy.
Dioxins	A family of compounds that are byproducts of some manufacturing and incineration processes. The uncontrolled burning of residential waste is thought to be among the largest sources of dioxins in the United States. ¹³ The bleaching process used to produce most paper and cotton products also releases dioxins into the environment. Because dioxins accumulate and persist in fat, a major source of exposure for humans is through contaminated foods like high-fat beef and dairy products.
Polybrominated biphenyls (PBBs)	Used as flame retardants in electrical appliances, textiles, plastic foams and other products. ¹⁴ In 1976 the manufacturing of PBBs ended in the United States after they contaminated milk supplies. ¹⁵⁻¹⁶
Polychlorinated biphenyls (PCBs)	A class of compounds that were used as coolants and insulation in electrical equipment, ¹⁷ in coating of electrical wiring and for many other purposes. They were banned in the 1970s due to their toxicity.
Phthalates	A family of compounds used as a plasticizer in PVC (vinyl), cosmetics, fragrance and medical products, such as slow-release pharmaceuticals, and plastic tubing and blood bags. Some phthalates were banned from children's products in 2008. ¹⁸
Phytoestrogens	Estrogen-like chemicals naturally found in plant foods such as beans, seeds, and grains. Soy, for example, contains the phytoestrogen genistein. ¹⁹ Even though some plants contain small amounts of naturally occurring hormone disruptors, there are many co-benefits from eating a plant-based diet.

Some hormone disruptors such as DDT,²⁰ PBBs,²¹⁻²² and PCBs²³ were banned more than 30 years ago but can still be found in the environment and in the bodies of people and animals to this day.

receptor lock, it triggers a process of sending messages to regulate functions in the body. Hormone disruptors can interfere with this process by scrambling these messages in different ways. For example, some can mimic natural hormones and bind to their receptors, triggering the process but sending the wrong message at the wrong time. Others can block

natural hormones from binding to their receptors at the appropriate time, keeping the right message from being sent.

Some hormone disruptors can change which genes are read and understood by the body, or they can change when genes are turned on and off at critical stages of development. Hormone disruptors can alter when a natural hormone is made or how much of a given hormone is destroyed and removed from the body. Interestingly, scientists are finding that some hormone disruptors have the ability to interfere with normal hormone signaling through several of these mechanisms. If exposure occurs at a critical time in development, even a very low dose of a hormone disruptor can throw the endocrine system off-balance, introducing an error in the development of a tissue or system that may not be apparent until much later, like leaving a brick out of a building's foundation.

Getting Perspective: The Historical Context

Wildlife observations and unfortunate human tragedies caused the scientific community to re-evaluate what was known about reproductive health and the environment in the 20th century. The following past discoveries laid the foundation for current scientific directions.

The Myth of the Impermeable Placenta

A mother's exposure to environmental contaminants can affect the future health of her children and possibly grandchildren. We did not always know this. We used to think the placenta, which provides blood, oxygen, and nutrients to a developing fetus, was a virtually impermeable shield protecting the fetus from harmful agents. There were several unfortunate incidences in the mid-twentieth century that disproved this theory. One of the most poignant was a tragedy involving a drug called thalidomide that demonstrated that pharmaceuticals taken during pregnancy could in fact harm a fetus.

Thalidomide was a sedative drug prescribed to pregnant women in the late 1950s and early 1960s to treat morning sickness and sleeplessness. The women who took it did not experience any side effects, but thousands of their babies were born with missing or severely disfigured limbs and other

birth defects. The tragedy underscored that if a pregnant woman is exposed to a chemical, her fetus can be harmed, even if she is unaffected. It also emphasized the importance of the timing of those exposures. With thalidomide, for example, children's limbs were affected only when the drug was taken within a specific time frame in the first trimester, during the period of fetal limb development.²⁴ The thalidomide tragedy and other similar occurrences demonstrate that the placenta is not an impermeable shield as was previously thought.

What Can We Learn from Alligators?

Since World War II, numerous chemical products have aided modern society, including pesticides, cosmetics, preservatives, cleaning products, pharmaceuticals, and plastics. PCBs (now banned) prevent fires in electrical transformers, DDT kills disease-carrying or crop-destroying insects, and BPA protects food cans



PHOTOS COURTESY OF LOUIS J. GUILLETTE, PH.D., UNIVERSITY OF FLORIDA

FIGURE 3: (left) A recently hatched alligator; (right) an adult American alligator feeding on its prey, Lake Apopka, Florida.

from corrosion and makes plastics clear and hard. Although man-made chemicals have benefited people's lives in many ways, they have also contaminated the environment.

Scientists began documenting the results of this contamination in the 1950s by observing wildlife populations. For years, researchers recorded declining or even disappearing populations of birds, fish, frogs, and other wildlife. They found that many of these animals were suffering from reproductive problems that could be linked to contamination of their habitats with hormonally active industrial chemicals.²⁴

One such finding involved the study of the American alligator in Lake Apopka, Florida. In 1985, University of Florida zoologist Dr. Louis Guillette Jr. and his team began studying alligators in Lake Apopka to better understand their reproductive biology. The team soon realized the alligators were suffering from reproductive failure. The male gators had abnormally small penises, and most of the eggs laid by female

alligators did not hatch. Half of the baby alligators that did hatch died within days. The researchers linked the alligators' reproductive problems to a severe chemical spill in 1980 that released pesticides into the lake. Right after the spill, more than 90 percent of the alligator population disappeared. But, subsequent samples of the lake water showed the original pesticide contamination had cleared, suggesting the alligator population should no longer be impacted.²⁴

Once the research team considered hormone disruption as a possible underlying cause of the continuing reproductive failure, everything became clear. The pesticides, which had accumulated in the alligators' bodies, were hormonally active. They were disrupting the alligators' reproductive systems, even at very low doses.²⁵ In addition, mother alligators were passing accumulated pesticides on to their offspring through the yolks of their eggs.²⁶ Lab studies confirmed these findings and also showed that female alligators exposed to the same pesticides during critical periods of development had ovarian follicles that were producing multiple eggs per follicle when they should only be producing one.²⁷⁻²⁸

Many other wildlife studies have provided "canary in the coal mine" warnings about hormone disruptors and our own reproductive health. Numerous laboratory studies have confirmed what researchers have observed in wildlife populations. Both wildlife and laboratory studies have helped scientists understand and predict how hormone disruptors can increase our risk for various health problems. Although hormone activity varies across species, the underlying genes and cellular mechanisms controlling reproductive

Although hormone activity varies across species, the underlying genes and cellular mechanisms controlling reproductive development are nearly identical in all vertebrates, whether in alligators, mice or humans.²⁵

Hormone disruptor research has typically focused on estrogens. But endocrine disruption goes beyond estrogens, androgens, and the reproductive system. Hormone disruptors, for example, can also affect thyroid hormones. Thyroid disruption during development can have lifelong consequences because normal thyroid balance is critical for central nervous system development.³¹

development are nearly identical in all vertebrates, whether in alligators, mice, or humans.²⁵

Animal studies are vital for studying the impacts that hormone disruptors can have on human reproductive health, particularly in the absence of comprehensive human data. However, an accidental experiment in the mid-twentieth century demonstrated the devastating impact exposure to a hormone disruptor could have on the development of the human female reproductive system.

Tragic Lessons: Fetal Origins of Adult Disease

In the late 1940s, pregnant women with a history of miscarriage or premature birth were offered a new preventative drug: an estrogenic pharmaceutical called diethylstilbestrol (DES). An estimated 5–10 million pregnant women and their children were exposed to DES.²⁹ Although there was little evidence to show the drug actually worked, doctors continued to prescribe DES until 1971, when an account

was published of several young women with a rare vaginal cancer. Their mothers had taken DES during pregnancy.

Until that time, this type of vaginal cancer, called clear cell adenocarcinoma, had virtually never been reported in women under 50.³⁰ As researchers explored the health of “DES daughters” further, they discovered that prenatal exposures to DES had caused other reproductive tract abnormalities and health problems, including decreased fertility, increased risk of ectopic pregnancy (when a fertilized egg implants outside the uterus), increased breast cancer risk, and early menopause.¹

DES taught us three important lessons that can guide our investigations of other chemicals:

- Exposure to hormone disruptors during fetal development can induce reproductive tract defects or other health impacts in the fetus, even if exposure does not affect the mother’s health.
- The risk of health impacts from exposure to hormone disruptors is especially high during prenatal development.
- A disease induced during development might only be apparent decades later, and exposure to this one chemical could lead to multiple health risks. Girls who were exposed to DES prenatally appeared to develop normally. Only in adulthood did health impacts like uterine malformations, infertility, vaginal cancer, and breast cancer become apparent.

These lessons continue to teach scientists about the risks of modern hormone disruptors and can help our society avoid another chemical tragedy.

Scientific Evolution

Building on past discoveries and research, scientists continue to refine what we know about hormone disruptors and their effects on female reproductive health and development. Our understanding of health risks continues to evolve and reflect the complexity of chemical impacts to health.

We now know that most disease is caused by interactions between a woman’s genetic makeup and the chemistry of her environment, rather than genetics alone. We know that high dose toxicology studies

may not accurately predict low dose effects. We know that health impacts from hormone disruptors depend on when exposure occurred, and that disease might only become obvious years or decades later. We

know that exposures of one generation can affect the next generation. Finally, we know that development of one reproductive disorder can indicate increased risk for other disorders because the entire reproductive system depends on the same hormonal signals and developmental architecture.

BPA, A Modern Day Human Health Threat: Lessons Learned from DES?

The wisdom we gained from the tragic lessons of DES is now being applied to chemicals with like properties such as bisphenol A (BPA). BPA is also a synthetic estrogen, and appears to act in similar ways to DES. In fact, BPA was intended for use as an estrogenic drug in the 1930s, but was abandoned when DES was found to be more potent.³² Today, BPA is used in a variety of common products, including baby bottles, food containers, sport water bottles, dental sealants, and in the linings of food cans. The chemical can leach into foods and liquids. Annual worldwide BPA production is estimated to be 6.4 billion pounds.³³ The Centers for Disease Control and Prevention (CDC) detected BPA in nearly 93 percent of the people they tested,³⁴ raising new questions about its widespread use.

BPA has been linked to a variety of health problems, including changes in behavior,³⁵ prostate cancer,³⁶ diabetes, obesity, and cardiovascular disease.³⁷⁻³⁸ Many studies also confirm a link between BPA and female reproductive health problems. Studies in which mice were exposed to BPA during fetal development or just after birth showed significant female reproductive system effects such as altered mammary gland development that led to significant changes in adult mammary gland composition. Exposed mice also had irregular or longer fertility cycles and accelerated puberty. These changes may serve as harbingers of later health problems such as breast cancer, changes in lactation, or reduced fertility.¹ The few existing human studies also show reasons for concern. BPA can cause human breast cancer cells to grow and replicate in the lab³⁹ and become resistant to chemotherapeutic agents.⁴⁰ A study of normal human breast tissue found that BPA induced changes associated with highly aggressive breast cancer tumors and poor survival rates.⁴¹ In Japan,

researchers described a link between BPA levels in the body and recurrent miscarriage.⁴²

The effects in animals, the small but important body of knowledge about BPA's effects on human health, and the widespread human exposure has led to the international questioning of BPA's safety. The potential for such harm has been, and continues to be, an area of intense debate among national governments. Currently, the U.S. and European food safety authorities approve BPA as a food additive.⁴³⁻⁴⁴ However, Canada has banned the use of BPA in baby bottles and is evaluating its use in canned food.⁴⁵ At the time of this printing, despite the many scientific reasons for concern, the U.S. federal government has not taken any action to limit the use of BPA.

"Safe" Levels of Exposure: Not So Safe After All

For years, it was assumed that low levels of chemical exposure would not harm our health. This assumption rested upon a classic idea in toxicology that is often summed up in the phrase "the dose makes the poison." This idea holds that increasing doses of exposure to a given toxic substance are associated with increasing levels of harm. For example, the more alcohol someone consumes, the more likely that person is to develop liver disease.

Congruently, the idea holds that if a person is exposed to a small enough dose of the substance, he or she will not be at risk of suffering any health effects. Based on this premise, toxicologists have traditionally assessed chemical risk assuming that there must be a "safe" dose at which levels are too low to cause any real harm. But we are finding that this is not true, particularly when we look at large populations with differences in age, disease status and genetics.

Hormone disruptors are one class of chemicals that illustrate why low levels of chemical exposure matter. Very small amounts of the body's natural hormones play a major signaling role in development, such as triggering and controlling the unfolding of puberty. So the endocrine system is responsive to even tiny doses of hormone disruptors. It is not that hormone disruptors have no effect at these low doses—they simply have different effects. In fact, exposure to




FIGURE 5: Hormone Activation Levels: Natural or synthetic hormones can activate changes at very low levels. This graph shows normal levels of natural estrogen (estradiol) in women and levels of synthetic estrogen (ethinyl estradiol) in women taking birth control pills. These levels are adequate to activate significant functions, such as regulating menstrual cycles and preventing pregnancy, respectively. BPA, which can mimic natural estrogen, can be found in the body under normal conditions at the same or higher levels than natural or synthetic estrogen. BPA is less potent than natural estrogen, but these levels are troubling.

a small amount of a hormone disruptor can have a graver impact than exposure to a large amount.

Researchers recently reported that mice exposed to extremely low levels of DES in the womb grew to be extremely obese in adulthood, whereas mice exposed to higher levels of DES actually lost weight in adulthood.⁴⁶ Likewise, some studies have found that very low levels of BPA can harm reproductive health in female mice⁴⁷ and their offspring.⁴⁸ More research is needed to fully understand how BPA impacts humans. The ubiquitous chemical has been found in women at levels that are within the range studied in many animal models,¹ and at the same or higher levels than natural estrogen and synthetic estrogen in

PHOTO COURTESY OF RETHA NEWBOLD, PH.D., NIHS



FIGURE 4: Mice exposed to low levels of DES in the womb grew to be extremely obese in adulthood (right), when compared to mice that were never exposed (left). Further, mice exposed to higher levels of DES actually lost weight in adulthood.

women taking birth control pills (levels that are sufficient to activate hormonal changes in the body).⁴⁹⁻⁵¹ Although BPA is less potent than natural estrogen (meaning it will not bind to the body's natural estrogen receptors as readily), these levels are troubling.

Additionally, people are exposed not merely to one hormone disruptor at a time, but to multiple hormone disruptors throughout their daily lives that can have additive and cumulative impacts.

A Toxic Legacy: Multigenerational Effects

Animal studies and DES daughters continue to teach us about the consequences of developmental hormone disruption. Researchers are now finding that the DES legacy may include the *granddaughters* of the women who took the drug. Preliminary research has found a higher than normal incidence of menstrual irregularities and potential infertility among DES granddaughters.⁵² Thus, women who never took DES themselves can be affected by their mothers' or

“Women who never took DES themselves can be affected by their mothers’ or grandmothers’ exposure.”

grandmothers' exposure. Studies with mice have shown that exposure to DES increases susceptibility to uterine tumors and that the trait is passed through the maternal line to subsequent generations.⁵³

Timing Matters: Exposure During Critical Stages of Development

The women's environmental reproductive health researchers at the January 2008 meeting identified a recurring theme throughout the scientific literature — that women and girls are particularly sensitive to the effects of hormone disruption during specific windows of vulnerability, or stages of rapid hormone-driven development. Grave impacts on the endocrine, immune, and neurological systems can occur if exposure to hormone disruptors takes place during fetal development and throughout childhood.

Prenatal and newborn exposures to hormone disruptors can be especially damaging because tissues and organs are just forming, setting the foundation for future reproductive health. Errors made during this critical period of development may not manifest until years later. For example, lab studies have shown that exposing rats and mice to DES in the womb or just after birth can give them a higher risk of developing uterine fibroids (benign tumors of the uterus) when they reach adulthood.⁵⁴⁻⁵⁶

Researchers observed that exposing female rats to DES at specific stages of uterine development permanently “programmed” genes in the uterus to be more sensitive to estrogen in adulthood, before tumors were seen. This hypersensitivity made the rats more susceptible to uterine fibroids. When rats with an inherited gene defect that made them more likely to develop tumors were also exposed to DES in the womb or just after birth, they ended up with even more tumors than the DES-exposed rats without the gene defect. Further, their tumors grew larger and faster.⁵⁴⁻⁵⁵ There is some indication that the same proves true for women exposed to DES in the womb, but more research is needed to confirm this link.⁵⁷

Figure 6 was adopted from the science manuscript that resulted from the Women's Reproductive Health and the Environment Workshop. It shows the known critical stages of development for several female reproductive disorders. Exposure to hormone




FIGURE 6: The known critical stages of development for several female reproductive disorders. Exposure to hormone disruptors during these windows increases a woman's risk of developing the associated health problem(s). Redrawn from Crain et al. (2008).¹

disruptors during these windows increases a woman's risk of developing the associated health problem(s).¹ The existing research shows that prenatal development (particularly during organogenesis, or the process of organ formation) and very early life (neonatal development) are critical periods of reproductive

system development. It is important to note that scientists are also concerned about other stages of development, such as puberty, but more research is needed to understand the reproductive health risks associated with exposure during puberty and other stages of development.

Development, Disrupted

Research shows that humans and animals are most vulnerable to hormone disruption during prenatal development, when a fetus is undergoing rapid, hormonally orchestrated change. Other crucial points in time when the endocrine system is particularly sensitive to hormone disruption include early life development, puberty, pregnancy, and lactation.

A Brief Look at Female Reproductive Development

Development of the female reproductive system begins in the early weeks of human pregnancy, with genes and hormones precisely orchestrating the occurrence and timing of key events. An enormous amount of growth and differentiation occurs during fetal development. The mammary glands, ovaries, and female reproductive tract (fallopian tubes, uterus, cervix, and vagina) all begin forming during the first trimester. Normal hormonal signaling at this time is critical to future reproductive health. After birth, growth and differentiation of the reproductive system slow dramatically until another series of important hormonal changes begins with puberty. As a result, the impact of hormone disruption during prenatal development may only become evident many years later.

For example, at birth, egg cells in the ovary are individually surrounded by supporting cells, called granulosa cells. These clusters form single follicles that wait for hormonal signals to stimulate further development when a girl reaches puberty. Prenatal follicular development hinges on the balance between estrogen and other hormones within the developing ovary. If balance during this critical time frame is disrupted, ovarian follicle formation can be impaired and the effects undetectable until some point after puberty when the follicle matures. This interference in development can potentially lead to a number of ovarian disorders in women, like polycystic ovarian syndrome (PCOS) and premature ovarian

failure (POF), both of which can impair fertility. Follicle health is particularly important because girls are born with all the egg cells they will ever have. The egg cells can be dormant for up to 50 years, during which time they are subject to a lifetime of environmental exposures.

Puberty marks the development of adult reproductive capacity, arising from the hormone-driven maturation of certain parts of the brain, ovary, uterus, and breasts. A hormonal cascade of events, beginning with a signal from the brain, stimulates the ovaries to begin producing estradiol (the principle natural estrogen in women and most other vertebrate females), which in turn initiates breast development and the maturation of the uterus. At this time, pubic hair also begins to grow and ducts in the breasts branch out and differentiate. Breast tissue will again undergo hormone-controlled changes during pregnancy and lactation.

About two years after the start of puberty, menstruation begins, signaling that ovulation has occurred. Ovulation depends upon the pituitary (a gland at the base of the brain) releasing a hormone called follicle-stimulating hormone, which triggers the maturation of several follicles within an ovary that begin to produce estrogen. Eventually, one follicle dominates and the others die off. When the dominant egg has matured, elevated blood concentrations of estrogen produced by the competing follicles, along with other hormonal signals, promote a surge of luteinizing hormone from the pituitary. This




IMAGE COURTESY OF PATRICIA HUNT, PH.D., WASHINGTON STATE UNIVERSITY

FIGURE 7: Follicle development: Egg development is a three-stage process, beginning during prenatal development and continuing through birth to puberty. At birth, egg cells in the ovary are individually surrounded by supporting cells, called granulosa cells. These clusters form single follicles that wait for hormonal signals to stimulate further development when a girl reaches puberty, at which time the monthly cycle of ovulation and menstruation ensue.

surge in turn triggers ovulation, which is the release of the lone egg cell into the fallopian tube. In this way, the pituitary and the ovaries communicate with one another through hormone signaling to regulate the monthly ovulation cycle.

If the egg remains unfertilized, menstruation ensues and another cycle begins. Eventually, egg cells are no longer released and the monthly cycle comes to an end (menopause). Hormones and reproductive organs continue to play an important role in a woman's health as she ages.

Reproductive Health Concerns of Women and Girls

The researchers who gathered at Commonweal in January 2008—in addition to reviewing what is known about effects of hormone disruptors on female reproductive development—explored whether a unifying hypothesis, a counterpart of the testicular dysgenesis syndrome, could be proposed to explain the onset of common female reproductive disorders. Below is a list of some female reproductive health problems and examples of their relationships to hormone disruptors.

Early Puberty

Early puberty is a growing concern. The age of puberty onset has declined over the last half century in several industrialized nations.⁵⁸⁻⁶⁰ In the United States, girls get their first periods a few months earlier than they did 40 years ago, and they develop breasts

one to two years earlier.⁶¹ Many scientists are troubled by this statistic. Girls who go through puberty early are at an increased risk for depression, sexual victimization, obesity, polycystic ovarian syndrome, breast cancer, and a number of social challenges such as experimentation with sex, alcohol, or drugs at a younger age.⁵⁸

The hormonal cues that initiate the onset of puberty are sensitive to a variety of environmental influences. Environmental factors thought to play a role in early puberty include obesity, increased nutrition, psychosocial stress, exposure to environmental pollutants, and exposure to more daylight hours via artificial lighting at night.¹ Prepubertal stages of development, such as in the womb and in early life, are thought to be vulnerable windows for hormone disruption that can lead to the early onset of puberty.¹ In animal and human studies, early puberty has been linked to greater cumulative estrogenic exposure to multiple contaminants, such as phthalates,⁶²⁻⁶³ BPA,⁶⁴ DES,⁶⁵ and some phytoestrogens like those found in soy formula.⁶⁵⁻⁶⁷ Early puberty is also associated with early life exposure to PCBs,⁶⁸ PBBs,⁶⁹ cigarette smoke,⁷⁰ and organochlorine pesticides like DDT and DDE.⁷¹⁻⁷⁴

There is also evidence that other contaminants, such as lead, can delay puberty.⁷⁵ Reduced environmental lead levels over the past 40 years could be contributing to earlier onset of puberty. This observation illustrates the complexity of interactions among the cocktail of contaminants that any one woman is exposed to during her life.

Impaired Fertility/Infertility

Impaired fertility or infertility includes the difficulty or inability to get pregnant and/or carry a pregnancy to term. It is hard to determine exactly how many people experience impaired fertility, but the best estimate is 12 percent of the reproductive-age population in the United States. As was noted previously (on page 7), this number seems to have increased over the last two decades, most sharply in women under the age of 25.⁵⁻⁷

There are many causes of impaired fertility. A woman's fertility depends on several body parts working together to produce and transport a healthy

egg and nurture the developing fetus. Conception and fetal health also depend on the quality of the father's sperm. Hormone disruptors can affect both parents, and scientists have linked fertility problems to exposure to DDT,⁷⁶⁻⁷⁸ DES,⁷⁹⁻⁸⁰ BPA,⁴² cigarette smoke,⁸¹⁻⁸² and PCBs.⁸³⁻⁸⁵


A number of female reproductive disorders can impair fertility, including abnormal numbers of chromosomes in the eggs, menstrual irregularities, polycystic ovarian syndrome, endometriosis, premature ovarian failure, and disorders associated with pregnancy, the three most common of which are miscarriage, preeclampsia, and intrauterine growth restriction. All of these disorders are discussed in greater detail in later sections.

Abnormal Number of Chromosomes (Aneuploidy)

An abnormal number of chromosomes, or aneuploidy, is a condition in which the fertilized egg has extra or missing copies of chromosomes. In humans, aneuploidy is the leading cause of early miscarriage and birth defects. One example is Down syndrome. It is thought to result from errors in chromosome segregation during the cell divisions that give rise to the mature egg.

For still unknown reasons, aneuploidy increases significantly as women age. While studying the phenomenon in adult mice, researchers inadvertently discovered that exposure to BPA caused a dramatic increase in the incidence of aneuploidy. Further investigation revealed that very low levels of BPA, levels to which humans are normally exposed, can cause chromosomal problems that can lead to the production of aneuploid eggs and embryos in mice exposed prenatally and as adults.⁴⁷⁻⁴⁸ Figure 8 shows two examples of chromosomal alignment during cell division. The top is normal. Chromosomes (stained red) are aligned properly. The bottom photo shows alignment in a cell exposed to BPA. Chromosomes are scattered throughout the cell. In this case, chromosomes are unlikely to be distributed properly, resulting in aneuploidy.

Human studies examining aneuploidy rates in women exposed *in utero* to BPA or other hormone disruptors have not yet been conducted, but animal studies are instructive for humans because cell



PHOTOS COURTESY OF PATRICIA HUNT, PH.D., WASHINGTON STATE UNIVERSITY

FIGURE 8: When a cell is dividing, the DNA condenses into paired structures called chromosomes. As cell division progresses, half of the parent chromosomes are drawn to each side of the dividing cell. The photographs above show two examples of chromosomal alignment during cell division. The top is normal. Chromosomes (stained red) are aligned properly. The bottom shows alignment in a cell exposed to BPA. Chromosomes are scattered throughout the cell. When cell division is completed by the exposed cell, chromosomes are unlikely to be distributed properly, resulting in aneuploidy.

division in mice is extremely similar to cell division in humans.

Miscarriage, Preeclampsia, Intrauterine Growth Restriction (IUGR), and Preterm Delivery

Miscarriage, preeclampsia (characterized by hypertension during pregnancy), intrauterine growth restriction (IUGR, poor weight gain during fetal development), and preterm delivery are common disorders of pregnancy. They can be due to poor

implantation, when the embryo does not properly attach to the uterus and the placenta does not fully develop.⁸⁶⁻⁸⁷ Miscarriage affects up to 21 percent of known pregnancies⁸⁸⁻⁹⁰ and can be caused by a variety of factors, including aneuploidy, environmental and dietary exposures, poor sperm quality, and hormone or immune system disruption.⁹¹ Women with diabetes are also at higher risk for miscarriage.⁹²

Both preeclampsia and IUGR carry increased risk of low birth weight,⁹³ preterm birth,⁹⁴ stillbirth, or newborn death.⁹⁵⁻⁹⁷ These links are important because low birth weight and preterm birth are important factors that can influence future health.⁹⁸⁻⁹⁹ Preterm delivery is the primary cause of death in the first month of life, and can lead to increased risk of childhood and adult illness.⁹⁹ Hormone disruptors have been linked to a variety of adverse pregnancy outcomes,¹⁰⁰ but the Bolinas workshop focused on miscarriage, preeclampsia, and IUGR.

Although few studies have linked hormone disruptors to preeclampsia specifically, several studies have shown an association with poor development of the placenta, IUGR, and/or miscarriage. In humans, first trimester exposure of fetuses to hormonal contraceptives such as Depo-Provera was shown to increase the risk for IUGR.¹⁰¹ Pesticides such as DDT/DDE^{77,102} have been linked to both IUGR and an increased risk of miscarriage. A 2003 review found that DES actually increased the risk of miscarriage for many women (rather than preventing miscarriage as was the drug's intended use).¹⁰³ Further, human placenta cells have been shown to grow less and exhibit increased cell death when they are exposed *in vitro* (in the laboratory) to DES, in addition to estrogen and the pesticides glyphosate, Roundup (a glyphosate-based herbicide), and methoxychlor.¹⁰⁴⁻¹⁰⁵

In mice, first trimester exposure to BPA was shown to decrease growth of the placenta, and increase miscarriage and infant mortality.¹⁰⁶ IUGR associated with poor placental growth was observed in pregnant rats exposed to estrogen.¹⁰⁷ These *in vivo* (within a living organism) and *in vitro* studies suggest that exposure to hormone disruptors during early pregnancy can reduce placental growth, which can reduce nutritional support to the embryo and lead to IUGR, or, in extreme cases embryonic or fetal mortality.

Menstrual Irregularities

The female menstrual cycle is highly regulated by a variety of hormones. Hormone disruptors can interfere with menstruation through multiple pathways, resulting in irregular periods, shorter or longer cycles, and fertility problems.¹ Human studies suggest that adult exposures to hormone disruptors such as PCBs,¹⁰⁸ DDT,⁷¹ and other pesticides¹⁰⁹⁻¹¹⁰ can impact future menstrual cycles. Scientists are concerned that fetal exposure to hormone disruptors might also impact future menstrual cycles. This concern has been well supported by animal studies. Although rodents do not menstruate, they do have fertility cycles that can serve as a model for human menstruation. Prenatal and newborn exposure to hormone disruptors such as BPA and some phytoestrogens have been shown to alter the mouse fertility cycle,¹¹¹⁻¹¹³ and to prematurely end cyclicity altogether.¹¹⁴ Few human studies exist, but some studies of dioxins¹¹⁵ and PCBs¹¹⁶ have shown that fetal exposures can lead to menstrual cycle irregularities later in life. Additionally, women whose mothers were exposed to DES while pregnant have reported cycle irregularities.⁵² More research is needed, but there is sufficient scientific evidence to suggest that exposure to hormone disruptors can impact menstruation in women and girls.

Polycystic Ovarian Syndrome (PCOS)

Polycystic ovarian syndrome (PCOS) is a multifaceted disorder affecting metabolism and reproduction, and is rooted in prenatal development.¹¹⁷ The syndrome includes insulin resistance, diabetes, high cholesterol, high blood pressure, high androgen (for example, testosterone) production, and premature pubic hair growth.¹¹⁸ Irregular periods, abnormal bleeding, pelvic pain, ovarian cysts,¹¹⁹ and excess hair on the face and body are common symptoms, and a characteristic feature is an overabundance of maturing follicles in the ovaries. No single follicle is dominant as would be normal. An estimated four to eight percent of women in their childbearing years are affected by PCOS and face a higher risk of developing insulin resistance, diabetes, endometrial cancer, infertility, miscarriage, and hypertension.¹²⁰⁻¹²² Annual evaluation and healthcare costs associated with PCOS have been estimated to be \$4.36 billion.¹¹⁸

PCOS has been linked to exposure to high androgen levels during prenatal development of the ovary and follicles.¹ It has been well documented that high testosterone levels during fetal development leads to PCOS in adult monkeys¹²³ and sheep,¹²⁴⁻¹²⁵ and high androgen and testosterone levels have also been associated with PCOS in humans.¹²⁶⁻¹²⁷ Scientists are concerned that exposure to hormone disruptors such as BPA during follicular development in the womb can also cause changes to hormone levels that lead to PCOS in girls and women.¹ BPA has been found in the follicular fluid of women with PCOS and in their fetus' blood,¹²⁸ and women with PCOS were found to have five times more BPA in their amniotic fluid compared to other women.¹²⁹ It is not yet clear if BPA exposure promotes PCOS, or if the presence of PCOS reduces how quickly a woman's body can clear BPA. More research is needed to know what effect BPA and other hormone disruptors might have on the progression of PCOS, but the fact that hormones play such a vital role during prenatal ovarian development indicates that PCOS could be initiated by environmental exposures.

Multi-oocyte Follicles (MOFs)

Multi-oocyte follicles (MOFs), or polyovular follicles, are defined as ovarian follicles containing several egg cells rather than a single one as should occur normally. In women, MOFs are associated with diminished *in vitro* fertilization success and increased early miscarriage.¹³⁰ Additionally, the presence of MOFs (also called biovularity) in women has been associated with ovarian teratomas, a type of tumor present from birth although it may not be detected until adulthood.¹³¹

As previously discussed (on page 12), multiple eggs per follicle can be induced in alligators by embryonic exposure to hormonally active pesticides.²⁵ Other estrogenic chemicals such as DES have also been shown to cause MOFs in mice.¹³²⁻¹³³ In both alligators and mice, adult reproduction appears to be impaired by this condition. These animal studies give scientists pause because the mechanism of damage appears to involve a signaling route that is also critical in human ovarian development. MOFs have been shown to occur in women,^{130,134-135} however more research is




FIGURE 9: Photographs of multi-oocyte follicles, or ovarian follicles containing several egg cells (top, two; bottom, multiple) rather than a single one as should occur normally.

needed to understand the role hormone disruptors might play in causing MOF formation in humans.

Uterine Fibroids

Uterine fibroids are benign tumors of the uterus that occur in 25 to 50 percent of all women, though some estimates are much higher.¹³⁶ Fibroids are the number one cause for hysterectomy in reproductive-age women,¹³⁷ and can cause pelvic pain, heavy periods and abnormal bleeding, infertility, and complications in pregnancy.¹³⁸⁻¹⁴³ Annual economic costs due to abnormal bleeding, often a symptom of fibroids, top \$1 billion and \$12 billion in direct and indirect expenses, respectively.¹⁴⁴ Hormone-associated risk factors include obesity and age of first menstrual period, while use of oral contraceptives, having multiple pregnancies, and menopause actually reduce the risk of developing fibroids.^{136,141,145-148}

Uterine fibroids are found in mice, some dogs, and Baltic gray seals with high body burdens of organochlorine pesticides.¹⁴⁹⁻¹⁵⁰ As was discussed previously (on page 16), rodent studies have shown that exposure during prenatal and early life stages to DES can lead to a higher risk of developing uterine fibroids in adulthood.⁵⁴⁻⁵⁶ DES and several pesticides also cause the cells of uterine fibroids taken from rats to multiply abnormally fast in the laboratory,¹⁵¹ suggesting that adult exposures to these compounds can promote uterine fibroid growth. Another recent study has shown that environmentally relevant levels of BPA (or levels to which women are currently exposed) can also increase the risk of uterine fibroids in adult mice, when exposure occurs during fetal development and just after birth.¹⁵² Human data is more limited,^{57,153} but there is concern that hormone disruptors such as BPA might be harmful to women, particularly at critical stages of uterine development. More research is needed to fill this information gap.

Endometriosis

Endometriosis occurs when the tissue that normally lines the inside of the uterus (called the endometrium) grows outside the uterus on other internal parts of the body, for example the ovaries, abdomen, and pelvis. This chronic disease is a major contributor to female infertility and causes inflammation, pain, and scarring. Estimates vary, but most studies find between 10 and 15 percent of reproductive-age women have endometriosis.¹⁵⁴⁻¹⁵⁵ Some women appear to be more susceptible to developing endometriosis due to immunological or hormonal factors, and endometriosis usually regresses after menopause or surgical removal of the ovaries.¹ Between 35 and 50 percent of women with pelvic pain, infertility, or both have endometriosis, yet it appears to be both under diagnosed and undertreated.¹⁵⁶⁻¹⁵⁷ U.S. healthcare and loss of productivity costs associated with this disorder were estimated to be \$22 billion in 2002 alone.¹⁵⁸

Overwhelming evidence from animal studies involving monkeys and mice show a link between endometriosis and exposure to organochlorine compounds, including DDT, the pesticide methoxychlor, dioxin, and several PCBs that act like dioxin.¹⁵⁹⁻¹⁶⁵ In humans, a few studies have also

associated endometriosis with dioxin,¹⁶⁶⁻¹⁶⁷ phthalates,¹⁶⁸⁻¹⁶⁹ and PCBs.¹⁷⁰⁻¹⁷⁶ Most research on an environment-endometriosis link has focused on adult hormone and hormone disruptor levels; however, some research suggests that fetal exposures affect later development of this disorder.¹ First, an on-going study of healthy women reported that DES daughters have an 80 percent higher risk of developing endometriosis.¹⁷⁷ Second, prenatal exposure to dioxin has been shown to promote endometriosis in mice.¹⁷⁸ It also has been suggested that prenatal exposures to organochlorines can program uterine tissue in such a way that it is more likely to develop endometriosis following secondary exposures in adulthood.¹ More research is needed to fully understand how both prenatal and adult exposure to hormone disruptors can impact endometriosis in humans.

Shortened Lactation

Shortened lactation, or reducing how long a woman can breastfeed her baby, can have long-term impacts on the child, including increased risk for infection, heart disease, compromised immunity, diabetes, and obesity.¹⁷⁹ Breastfeeding helps build a child's immune system and later intelligence and is important to the bonding and nurturing process.¹⁷⁹⁻¹⁸⁰ Additionally, breastfeeding is good for the mother. A lack of breastfeeding has been linked to higher disease risks for women such as osteoporosis and ovarian, uterine, endometrial, and breast cancers.¹⁸¹

During pregnancy through the first days after childbirth, breast growth and glandular changes set the stage for a woman's ability to breastfeed. Hormones such as estrogen and progesterone are key drivers of this preparation.¹⁸² Duration of lactation is reduced in women with increased blood levels of PCBs and DDT/DDE,¹⁸³ as can be the case for women who eat large amounts of Great Lakes fish or live near intensive agriculture.¹⁸⁴⁻¹⁸⁵ In addition, several recent animal studies have shown that fetal exposure to environmentally relevant levels of the herbicide atrazine can reduce breast development and decrease later milk production and duration of lactation.¹⁸⁶⁻¹⁸⁷ Atrazine is one of the most widely used herbicides applied in the United States today. It is broadly used on field crops and is the main herbicide

in “weed and feed” type lawn formulations purchased by homeowners.

Breast Cancer

Breast cancer incidence rates in the United States increased by more than 40 percent between 1973 and 1998. In 2008, a woman’s lifetime risk of breast cancer is one in eight.¹⁸⁸ Breast cancer arises from genetic, lifestyle and environmental causes, several of which relate to lifetime exposure to hormones (primarily estrogen). It is known that exposure to a high cumulative amount of estrogen across a woman’s lifespan increases her risk of breast cancer. This exposure varies by age at first menstrual period, first pregnancy, and menopause, and by breastfeeding and number of pregnancies. Lifetime estrogen exposure may also be increased by exposure to estrogenic hormone disruptors, birth control pills, and hormone replacement therapy.

More than 200 chemicals, including many hormone disruptors such as DES,¹⁸⁹⁻¹⁹² BPA,¹⁹³⁻¹⁹⁹ chemicals in first or second-hand smoke,²⁰⁰⁻²⁰⁶ and some pesticides, including DDT and atrazine,²⁰⁷⁻²⁰⁹ have been associated with an increased incidence of breast tumors in humans and/or lab animals.²¹⁰ Exposures during prenatal and pubertal development appear to be especially critical, although the specific details of how each chemical promotes cancer is not yet known. Additionally, breast cancer, like other reproductive disorders, probably results from disruption during more than one stage of breast development. A succession of exposure “hits” is needed, with early ones setting the stage and later ones promoting disease progression.

Studies of DES daughters, who are at an increased risk for breast cancer due to their prenatal exposure to DES,¹⁹⁰ provide a model for breast cancer development that is now being observed with other more widely encountered hormone disruptors such as BPA.¹ Current BPA studies are helping to clarify how hormone disruptors might affect breast development and differentiation. Animal studies, using levels of BPA to which women are exposed, have demonstrated several possibilities. For example, baby mice exposed to BPA were found to have mammary gland tissue comparable to the dense tissue of pregnant mice.¹⁹⁶ This

finding is a concern because increased breast density is a risk factor for breast cancer in humans.

Most human studies have focused on adult exposures; however, some retrospective studies provide hints that early hormone disruptor exposure has a role in adult disease. For example, although an earlier study showed no link between DDT and breast cancer, narrowing the suspected exposure to girls younger than 14 revealed a fivefold increase in breast cancer risk after age 50.²⁰⁷ Puberty is thought to be a critical window of sensitivity for exposure to hormone disruptors that can lead to breast cancer; however, puberty and subsequent development of breast cancer in adulthood needs to be more extensively studied.¹

Early Menopause

(Premature Ovarian Failure, POF)

Early menopause (or premature ovarian failure, POF) is a condition in which a woman ceases to menstruate before age 40.²¹¹ The average age of menopause for women in the United States is in the early 50s.²¹² POF appears to be due to genetic or immunological causes that result in too few follicles being created or too many dying early.²¹³ In addition to a premature loss of fertility, POF carries the burden of postmenopausal health risks such as cardiovascular disease and osteoporosis.²¹⁴ Very few studies examine environmental effects on menopause, although the theoretical possibility is recognized.²¹⁵

Like polycystic ovarian syndrome, POF is thought to originate from changes in hormone signaling during critical windows of prenatal follicle formation.²¹¹ Future studies on the impacts of hormone disruptors during this critical period are necessary to understand how the environment influences POF.¹

Tangled Links

As was stated earlier, many factors other than hormone disruptors can influence the reproductive health of women and girls including age, overall health, diet, obesity, level of physical activity, and socioeconomic status. Emerging research is revealing what seems to be a key link between female reproductive disorders and obesity. New studies are finding links between obesity and the incidence of

Table 2: Summary of Female Reproductive Health Concerns and Links to Hormone Disruptors Discussed in this Report

Female Reproductive Health Concern	Examples of Associated Hormone Disruptors
Early puberty	BPA, ⁶⁴ cigarette smoke, ⁷⁰ organochlorine pesticides such as DDT/DDE, ⁷¹⁻⁷⁴ DES, ⁶⁵ PBBs, ⁶⁹ PCBs, ⁶⁸ phthalates, ⁶²⁻⁶³ and some phytoestrogens ⁶⁵⁻⁶⁷
Impaired fertility or infertility	BPA, ⁴² cigarette smoke, ⁸¹⁻⁸² DDT, ⁷⁶⁻⁷⁸ DES, ⁷⁹⁻⁸⁰ and PCBs ⁸³⁻⁸⁵
Abnormal number of chromosomes (aneuploidy)	BPA ⁴⁷⁻⁴⁸
Miscarriage, preeclampsia, intrauterine growth restriction (implantation disorders)	BPA, ¹⁰⁶ DES, ¹⁰³⁻¹⁰⁴ and pesticides such as DDT/DDE, ^{77,102} glyphosate, Roundup, and methoxychlor ¹⁰⁴⁻¹⁰⁵
Menstrual irregularities	BPA and some phytoestrogens, ¹¹¹⁻¹¹⁴ DDT ⁷¹ and other pesticides, ¹⁰⁹⁻¹¹⁰ DES, ⁵² dioxins, ¹¹⁵ and PCBs ^{108,116}
Polycystic ovarian syndrome (PCOS)	BPA ¹²⁸⁻¹²⁹
Multi-oocyte follicles (MOFs)	DES ¹³²⁻¹³³ and some pesticides ²⁵
Uterine fibroids	DES, ^{54-57,151,153} BPA, ¹⁵² and some organochlorine pesticides ¹⁴⁹⁻¹⁵⁰
Endometriosis	Organochlorine compounds such as DDT, the pesticide methoxychlor, dioxin and several PCBs, ^{159-167,170-176,178} phthalates, ¹⁶⁸⁻¹⁶⁹ and DES ¹⁷⁷
Shortened lactation	The pesticide atrazine, ¹⁸⁶⁻¹⁸⁷ DDT/DDE, and PCBs ¹⁸³⁻¹⁸⁵
Breast cancer	More than ²⁰⁰ chemicals, including some hormone disruptors such as BPA, ¹⁹³⁻¹⁹⁹ chemicals in cigarette smoke, ²⁰⁰⁻²⁰⁶ DES, ¹⁸⁹⁻¹⁹² and some pesticides such as DDT and atrazine ²⁰⁷⁻²⁰⁹

* Although few studies have linked hormone disruptors to preeclampsia specifically, several studies have shown an association with poor development of the placenta, IUGR, and/or miscarriage.

Note: the above reproductive health concerns and their associated hormone disruptors are discussed in this report, but do not constitute an exhaustive list. For a descriptive list of hormone disruptors and sources of exposure see page 10.

hysterectomies and stillbirths. Higher body mass index has also been associated with earlier puberty in girls, while low physical activity in some women has been linked to an increased risk for endometriosis.

Furthermore, interesting relationships among multiple health factors including female reproductive disorders are emerging from current research. For example, children of women diagnosed with polycystic ovarian syndrome (PCOS) are more likely to be exposed to increased prenatal androgen concentrations, in addition to being born with a low birth weight.²¹⁶⁻²¹⁷ Low birth weight is a complication that

has in turn been linked to obesity, insulin insensitivity, and diabetes later in life.²¹⁸ This is especially true for those who are not breastfed or who are weaned from the breast early.²¹⁹⁻²²¹ Low birth weight has also been linked to early puberty, fertility problems, and PCOS in later life.²²¹

We know that hormones play a key role in the development of obesity and female reproductive disorders such as PCOS. However, in order to better understand how hormone disruptors might contribute to the picture, we need more research that clarifies these relationships. For example, obesity might

cause or exacerbate reproductive disorders in women. Or, perhaps obesity and some female reproductive disorders originate from similar prenatal and early life

exposure to hormone disruptors. This is a critical area of study, particularly because rates of obesity are rising rapidly in modern Western societies.

Answers, Questions, and the Future

What do we know about hormone disruptors and women's reproductive health and development? What do we still need to explore, and what should we do in the meantime to protect the reproductive health of current and future generations?

What We Have Learned

While we still need significant information, especially at the genetic level, on how the female reproductive health system develops, what causes problems with it, and how hormone disruptors modify reproductive function, we have come a long way in recent years. Here, in a nutshell, is what we know.

- **The placenta is not an impermeable shield** as was previously thought. A woman's exposure to chemicals during pregnancy can cross the placental barrier and harm a fetus, even if the mother's health is not impacted.
- **Animals count.** It was observations of reproductive abnormalities in wildlife that first sparked the idea of environmental hormone disruption. Humans and other animals have very similar genes and cellular mechanisms. Animal studies in the wild and the laboratory serve as warnings about threats to our own reproductive health.
- **Environmental factors such as hormone disruptors contribute** to women's reproductive health problems. Thus, if contaminant pollution is reduced, many female reproductive health problems could be prevented or made less severe.
- **The dose does not make the poison.** Unlike what we have learned from traditional schools of toxicological assessment that focused on high doses, low levels of hormone disruptors can have a negative impact on female reproductive health. Therefore, we cannot assume there are "safe" levels of exposure.

- New science is revealing that hormone disruptors can have **multigenerational effects**. An exposure to a woman during pregnancy can lead to reproductive health problems in her children, grandchildren, and potentially later generations.
- There are clear **windows of vulnerability**. The female reproductive system is particularly vulnerable to hormone disruption during periods of rapid body development or changes that are driven by hormones. This is particularly true during prenatal and early life development, but also during puberty and reproductive maturity.
- There are many **gaps in our understanding** of hormone disruptor and female reproductive health science. We have numerous studies that link hormone disruption to female reproductive disorders in animals, particularly when exposure occurs during critical periods of development (such as in the womb, in early life, and during puberty). But many of the mechanisms are poorly understood and human studies are limited. Further thought is needed for proposing a single common origin for multiple female reproductive health problems (similar to the testicular dysgenesis syndrome in males), but it is clear that prenatal exposures to hormone disruptors are critical. Secondary adult exposures are also important to consider, as they may exacerbate conditions that were set up prenatally. Focused research needs to be done in order to solve the puzzle and answer these key questions. As with any novel approach to understanding a problem, there is an immediate need for additional information.

Where Do We Go from Here?

The investigation of hormone disruptors and female reproductive health is critical. Women's reproductive health problems are common and can have a devastating impact on the lives of the women who suffer from them, as well as their families. Hormone disruptors are ubiquitous in the environment. Below are recommended actions that will help us better understand how hormone disruptors can impact women's health, and what we can do to protect ourselves from exposure.

1. Support better research on hormone disruptors and female reproductive health.

- *Prioritize research funding to study the effects of hormone disruptors on women's health.* Most of the research to date has been limited and focused on health outcomes in males, leaving large gaps in our understanding of how females may be impacted.
- *Improve health tracking systems.* Currently the systems that track rates of various health problems are inadequate. In order to understand the full impact of hormone disruptors on human health, particularly women's health, we need to track female reproductive health trends.
- *Assess chemicals for their hormonal and reproductive health effects.* Knowledge about the hormone-disrupting potential of most of the over 80,000 industrial chemicals in production is very limited. These chemicals also have not been systematically assessed for their effects on reproductive health. Since industrial chemicals occur in nearly everything we buy and also are found in food, air, and water, this is a crucial step. Increasing the use of *in vitro* and *in vivo* testing can help identify potentially harmful chemicals.
- *Investigate the impacts of hormone disruptor exposure during critical windows of vulnerability.* The major impediment to understanding whether hormone disruptors influence female reproductive disorders is the lack of information linking fetal exposures to adult-onset reproductive disorders in humans. We have come

to realize over the last decade that the embryonic/fetal origin of adult disease is a very real threat and requires significant research and a change in our approach to linking disease with exposure. We need to carefully examine human exposures—especially during prenatal, newborn, and pubertal development—and consider whether these exposures relate to particular reproductive health disorders later in life. Moreover, the hypothesis that secondary adult exposures may initiate or exacerbate conditions that were set up prenatally requires further investigation.

- *Support long-term studies.* Because hormone disruptors can have life-long impacts, it is especially important to initiate studies tracking women's health over large spans of their lives and to evaluate longer periods of time in animal studies. This will help us understand long-term and multigenerational effects.
- *Encourage collaboration.* Currently, most reproductive disorders are studied in isolation. This approach yields detailed information about single disorders, but it neglects commonalities that might exist among multiple disorders. By pooling data such as tissue samples and study results, a broader picture might emerge.

2. Support policies that require information on whether exposure to hormone disruptors and other chemicals can result in harm, and that prevent exposure to those that do.

Current policies for chemical use do not adequately protect us. New national policies are needed to identify and phase out harmful chemicals and to require that safer substitutes be used. Furthermore, current policies assume chemicals are safe until proven dangerous. A more prudent approach would entail testing before a chemical is put on the market and released into the environment. Chemicals currently on the market should be tested in order to remain on the market.

3. Use healthier products when possible.

Although we have much to learn about how chemicals impact human health, we know

enough to be cautious in the face of uncertainty. We can act now to protect ourselves from unnecessary exposures. We need to educate women and girls on ways to avoid exposures to chemicals that have been identified as reproductive and developmental toxins. There are many easy, affordable, and simple changes anyone can make at home to reduce their exposure to environmental contaminants. For ideas on how to make these changes, please see www.womenshealthandenvironment.org.

4. **Interdisciplinary cooperation.** The researchers that gathered in Bolinas in January 2008

represented a broad range of scientific and medical expertise, with researchers in reproductive medicine, toxicology, and zoology, among others, as well as representatives of non-profit, governmental, and academic organizations. An interdisciplinary consortium to coordinate research, policy, advocacy and education on the impact of hormone disruptors on reproductive health could build upon the accomplishments of the Women's Reproductive Health and the Environment Workshop. The ultimate goal of such an integrated consortium would be to collectively reduce the burden of reproductive disease for the next generation of women and girls.

Key Resources for Further Information on Female Reproductive Health and the Environment

- *Challenged Conceptions: Environmental Chemicals and Fertility*, a report that translates the science from a multidisciplinary workshop on fertility and the environment, held at the Vallombrosa Retreat Center in Menlo Park, California, in 2005. The workshop was titled Understanding Environmental Contaminants and Human Fertility Compromise: Science and Strategy and was convened by the Stanford University School of Medicine's Women's Health@Stanford Program and the Collaborative on Health and the Environment (CHE). www.healthandenvironment.org/infertility/vallombrosa_documents
- *Hormone Disruptors and Women's Health: Reasons for Concern*, a six-page summary brochure on the impacts of hormone disruptors on female reproductive health. The brochure highlights the key scientific takeaways from the Women's Reproductive Health and the Environment Workshop that are also translated in this report. www.healthandenvironment.org/reprohealthworkshop
- *Our Stolen Future* (www.ourstolenfuture.org). The book *Our Stolen Future*, authored by Theo Colborn, Dianne Dumanoski, and John Peterson Myers, presents the history and development of the hormone disruption hypothesis and explains how hormone disruptors affect animal and human health. The website serves as a sequel to the book and presents news and continuing research related to hormone disruptors.
- *Shaping Our Legacy: Reproductive Health and the Environment*, a nontechnical and comprehensive summary of the latest science on how exposure to chemicals may impair reproductive health. The report translates the science from the January 2007 Summit on Environmental Challenges to Reproductive Health and Fertility, and was produced by the Program on Reproductive Health and the Environment (PRHE) at the University of California, San Francisco (UCSF). The Summit was hosted by UCSF and CHE. www.prhe.ucsf.edu/prhe/pubs/shapingourlegacy.html

- *Silent Spring Institute* (www.silentspring.org). Rachel Carson's work continues through the nonprofit scientific research organization Silent Spring Institute. Institute scientists focus on identifying the links between the environment and women's health, with a particular emphasis on breast cancer.
- *State of the Evidence 2008: The Connection Between Breast Cancer and the Environment*, a comprehensive report on the environmental exposures linked to increased breast cancer risk, including natural and synthetic estrogens; xenoestrogens and other hormone-disrupting compounds; and carcinogenic chemicals and radiation. Published by the Breast Cancer Fund. www.breastcancerfund.org/evidence
- *The Falling Age of Puberty in U.S. Girls: What We Know, What We Need to Know*, the first comprehensive review of the literature on the timing of puberty. The Breast Cancer Fund commissioned ecologist and author Sandra Stein-graber to write *The Falling Age of Puberty* to help us better understand this phenomenon so we can protect our daughters' health. www.breastcancerfund.org/puberty

References

- 1 Crain DA, Janssen SJ, Edwards TM, Heindel J, Ho S, Hunt P, et al. Female reproductive disorders: the roles of endocrine disrupting compounds and developmental timing. *Fertil Steril* 2008;90:911–940. [www.fertstert.org/article/S0015-0282\(08\)03555-3/abstract](http://www.fertstert.org/article/S0015-0282(08)03555-3/abstract)
- 2 Environmental Protection Agency, HPV Chemical Hazard Data Availability Study, www.epa.gov/HPV/pubs/general/hazchem.htm. Viewed November 7, 2008.
- 3 Toppari J, Larsen JC, Christiansen P, Giwercman A, Grandjean P, Guillelte LJ Jr, et al. Male reproductive health and environmental xenoestrogens. *Environ Health Perspect* 1996;104(Suppl 4):741–803.
- 4 Hamilton BE, Ventura SJ. Fertility and abortion rates in the United States, 1960–2002. *Int J Androl* 2006;29:34–45.
- 5 Giudice LC, Swan SH, Myers JP, Carlson A. Vallombrosa Consensus Statement on environmental contaminants and human fertility compromise. *Semin Reprod Med* 2006;24:178–190.
- 6 Chandra A, Martinez GM, Mosher WD, Abma JC, Jones J. Fertility, family planning, and reproductive health of U.S. women; data from the 2002 National Survey of Family Growth. *Vital Health Stat* 2005;Series 23 #25:1–160.
- 7 Brett K. Fecundity in 2002 NSFG women 15–24 years of age. Hyattsville, MD: National Center for Health Statistics. Personal communication, April 22, 2008.
- 8 National Institute of Environmental Health Science Endocrine Disruptor factsheet. www.niehs.nih.gov/health/topics/agents/endocrine/docs/endocrine.pdf. Viewed August 12, 2008.
- 9 Atrazine US website. www.thecre.com/atrazine/intactions.htm. Viewed August 25, 2008.
- 10 Dodds EC, Lawson W. Synthetic oestrogenic agents without the phenanthrene nucleus. *Nature* 1936;137:996.
- 11 Dodds EC, Lawson W, Noble RL. Biological effects of the synthetic oestrogenic substance 4: 4'-dihydroxy- a: B-dimethylstilbene. *Lancet* 1938;234:1389–91.
- 12 Environmental Protection Agency Press Release. www.epa.gov/history/topics/ddt/01.htm. Viewed August 25, 2008.
- 13 Food and Drug Administration website. www.cfsan.fda.gov/~lrd/dioxinqa.html#g1. Viewed August 25, 2008.
- 14 Department of Health and Human Services Agency for Toxic Substances & Disease Registry, PBB factsheet. www.atsdr.cdc.gov/tfacts68.html. Viewed August 25, 2008.
- 15 Fries GF, Marrow GS, and Cook RM. Distribution and kinetics of PBB residues in cattle. *Environ Health Perspect*. 1978 April; 23: 43–50.
- 16 Department of Health and Human Services Agency for Toxic Substances & Disease Registry, PBB factsheet. www.atsdr.cdc.gov/tfacts68.html#bookmark02. Viewed August 25, 2008.
- 17 Department of Health and Human Services Agency for Toxic Substances & Disease Registry, PCB factsheet. www.atsdr.cdc.gov/tfacts17.html. Viewed August 25, 2008.
- 18 Breast Cancer Fund website. www.breastcancerfund.org/site/pp.asp?c=kwKXLdPaE&b=4132341. Viewed August 25, 2008.
- 19 Program on Breast Cancer and Environmental Risk Factors, Cornell University, Phytoestrogens and Breast Cancer Fact Sheet #01, revised July 2001. envirocancer.cornell.edu/FactSheet/Diet/fs1.phyto.cfm. Viewed November 7, 2008.

- 20 Centers for Disease Control and Prevention National Environmental Public Health Tracking Program webpage. www.cdc.gov/nceh/tracking/biomontrack.htm#exposures. Viewed August 12, 2008.
- 21 Lim JS, Lee DH, Jacobs DR. Association of brominated flame retardants with diabetes and metabolic syndrome in the US population, 2003–2004. *Diabetes Care* 2008;31(9):1802–7.
- 22 Zhu LY, Hites RA. Temporal trends and spatial distributions of brominated flame retardants in archived fishes from the Great Lakes. *Environ Sci Technol* 2004;38(10): 2779–84.
- 23 Centers for Disease Control and Prevention Third National Report on Human Exposure to Environmental Chemicals. 2005. www.cdc.gov/exposurereport/report.htm. Viewed August 25, 2008.
- 24 Colborn, T., D. Dumanoski, and J.P. Myers. 1996. *Our Stolen Future: Are We Threatening Our Fertility, Intelligence, and Survival? A Scientific Detective Story*. New York: Penguin Books USA Inc.
- 25 Kays J. For the good of gators and humankind. *HHMI Bulletin* 2007;20(2): 26–31.
- 26 Heinz GH, Percival HF, Jennings ML. Contaminants in American alligator eggs from Lake Apopka, Lake Griffin, and Lake Okeechobee, Florida. *Environ Monitor Assess* 1991;16:277–85.
- 27 Guillette LJ Jr, Moore BC. Environmental contaminants, fertility, and multioocytic follicles: a lesson from wildlife? *Semin Reprod Med* 2006;24:134–141.
- 28 Guillette LJ Jr, Edwards TM, Moore BC. Alligators, contaminants and steroid hormones. *Environ Sci* 2007;14(6):331–347.
- 29 Centers for Disease Control and Prevention, DES Update: Consumers, About DES. www.cdc.gov/DES/consumers/about/history.html. Viewed November 7, 2008.
- 30 Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. *N Engl J Med* 1971;284:878–881.
- 31 Boas M, Feldt-Rasmussen U, Skakkebaek NE, Main KM. Environmental chemicals and thyroid function. *European J Endocrin* 2006;154:599–611.
- 32 Background on BPA. www.ourstolenfuture.org/NewScience/oncompounds/bisphenola/bpauses.htm: Our Stolen Future.
- 33 Vom Saal FS, Hughes C. An extensive new literature concerning low-dose effects of bisphenol A shows the need for a new risk assessment. *Environ Health Perspect* 2005;113(8): 926–933.
- 34 National Report on Human Exposure to Environmental Chemicals Spotlight on Bisphenol A. www.cdc.gov/exposurereport/pdf/factsheet_bisphenol.pdf.
- 35 Leranath C, Hajszan T, Szigeti-Buck K, Bober J, MacLusky NJ. Bisphenol A prevents the synaptogenic response to estradiol in hippocampus and prefrontal cortex of ovariectomized nonhuman primates. *Proc Natl Acad Sci U S A* 2008;105(37):14187–91.
- 36 Prins GS, Tang WY, Belmonte J, Ho SM. Perinatal exposure to oestradiol and bisphenol A alters the prostate epigenome and increases susceptibility to carcinogenesis. *Basic Clinical Pharmacol Toxicol* 2008;102(2):134–8.
- 37 Hugo ER, Brandebourg TD, Woo JG, Loftus J, Alexander JW, Ben-Jonathan N. Bisphenol A at environmentally relevant doses inhibits adiponectin release from human adipose tissue explants and adipocytes. *Environ Health Perspect* 2008; doi:10.1289/ehp.11537
- 38 Lang IA, Galloway TS, Scarlett A, Henley WE, Depledge M, Wallace RB, Melzer D. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. *JAMA* 2008;300(11):1303–10.
- 39 Quitmeyer A, Roberts R. Babies, bottles, and bisphenol A: the story of a scientist mother. *PLoS Biology* 2007;5(7):1399–1402.
- 40 LaPensee EW, Tuttle TR, Fox SR, Ben-Jonathan N. Bisphenol A at Low Nanomolar Doses Confers Chemoresistance in Estrogen Receptor Alpha Positive and Negative Breast Cancer Cells. *Environ Health Perspect* 2008; doi:10.1289/ehp.11788. [Online 8 October 2008]
- 41 Dairkee SH, Seok J, Champion S, Sayeed A, Mindrinos M, Xiao W, et al. Bisphenol A induces a profile of tumor aggressiveness in high-risk cells from breast cancer patients. *Cancer Res* 2008;68(7):2076–80.
- 42 Sugiura-Ogasawara M, Ozaki Y, Sonta S, Makino T, Suzumori K. Exposure to bisphenol A is associated with recurrent miscarriage. *Hum Reprod* 2005;20(8):2325–2329.
- 43 www.fda.gov/oc/opacom/hottopics/bpa.html; Food and Drug Administration, U.S. 2008. Bisphenol A. www.fda.gov/oc/opacom/hottopics/bpa.html: U.S. FDA.
- 44 European Food Safety Authority. Opinion of the Scientific Panel on food additives, flavourings, processing aids and materials in contact with food (AFC) related to 2,2-BIS(4-HYDROXYPHENYL)PROPANE. 2006. www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_1178620772817.htm . Viewed November 7, 2008.
- 45 Government of Canada. Chemical Substances, an ecoACTION initiative. Government of Canada Protects Families With Bisphenol A Regulations. 2008. www.chemicalsubstanceschimiques.gc.ca/challenge-defi/bisphenol-a_e.html. Viewed November 7, 2008.
- 46 Newbold RR, Padilla-Banks E, Snyder RJ, Jefferson WN. Developmental Exposure to Estrogenic Compounds and Obesity. *Birth Defects Research (Part A)* 2005;73:478–480.
- 47 Hunt PA, Koehler KE, Susiarjo M, Hodges CA, Ilagan A, Voigt RC, et al. Bisphenol A exposure causes meiotic aneuploidy in the female mouse. *Curr Biol* 2003;13:546–53.

- 48 Susiarjo M, Hassold TJ, Freeman E, Hunt PA. Bisphenol A exposure in utero disrupts early oogenesis in the mouse. *PLoS Genet* 2007;3:e5.
- 49 Medline Plus Medical Encyclopedia: Estradiol. www.nlm.nih.gov/medlineplus/ency/article/003711.htm. Viewed August 12, 2008.
- 50 Drugs.com FDA Professional Drug Information for OrthoCept. www.drugs.com/pro/orthocept.html. Viewed August 12, 2008.
- 51 Welshons WV, Nagel SC, and vom Saal FS. Large effects from small exposures. III. Endocrine mechanisms mediating effects of Bisphenol A at levels of human exposure. *Endocrinology* 2006;147(6)(Supplement):S56–S69.
- 52 Titus-Ernstoff L, Troisi R, Hatch EE, Wise LA, Palmer J, Hyer M, et al. Menstrual and reproductive characteristics of women whose mothers were exposed in utero to diethylstilbestrol (DES). *Int J Epidemiol* 2006;35(4):868–70.
- 53 Newbold RR, Padilla-Banks E, Jefferson WN. 2006. Adverse effects of the model environmental estrogen diethylstilbestrol are transmitted to subsequent generations. *Endocrinology* 2006;147(6):S11–S17.
- 54 Cook JD, Davis BJ, Cai SL, Barrett JC, Conti CJ, Walker CL. Interaction between genetic susceptibility and early-life environmental exposure determines tumor-suppressor-gene penetrance. *Proc Natl Acad Sci USA* 2005;102:8644–9.
- 55 Cook JD, Davis BJ, Goewey JA, Berry TD, Walker CL. Identification of a sensitive period for developmental programming that increases risk for uterine leiomyoma in Eker rats. *Reprod Sci* 2007;14:121–36.
- 56 Newbold RR, Moore AB, Dixon D. Characterization of uterine leiomyomas in CD-1 mice following developmental exposure to diethylstilbestrol (DES). *Toxicol Pathol* 2002;30:611–6.
- 57 Baird R, Newbold R. Prenatal diethylstilbestrol (DES) exposure is associated with uterine leiomyoma development. *Reprod Toxicol* 2005;20: 81–84.
- 58 Sandra Steingraber. The Falling Age of Puberty in U.S. Girls: What We Know, What We Need to Know. Breast Cancer Fund. 2007. www.breastcancerfund.org/puberty.
- 59 Herman-Giddens ME, Slora EJ, Wasserman RC, Bourdony CJ, Bhapkar MV, Koch GG, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. *Pediatrics* 1997;99:505–12.
- 60 Parent AS, Teilmann G, Juul A, Skakkebaek NE, Toppari J, Bourguignon JP. The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration. *Endocr Rev* 2003;24:668–93.
- 61 Euling SY, HermanGiddens ME, Lee PA, Selevan SG, Juul A, Sorensen TI et al. Examination of US puberty-timing data from 1940 to 1994 for secular trends: panel findings. *Pediatrics* 2008;121 Suppl 3:S172–91.
- 62 Colon I, Caro D, Bourdony CJ, Rosario O. Identification of phthalate esters in the serum of young Puerto Rican girls with premature breast development. *Environ Health Perspect* 2000;108:895–900.
- 63 McKee RH. Phthalate exposure and early thelarche. *Environ Health Perspect* 2004;112:A5413.
- 64 Howdeshell KL, Hotchkiss AK, Thayer KA, Vandenberg JG, vom Saal FS. Exposure to bisphenol A advances puberty. *Nature* 1999;401: 763–4.
- 65 Brown NM, Lamartiñiere CA. Xenoestrogens alter mammary gland differentiation and cell proliferation in the rat. *Environ Health Perspect* 1995;103:708–13.
- 66 Freni-Titulaer LW, Cordero JF, Haddock L, Lebron G, Martinez R, Mills JL. Premature thelarche in Puerto Rico. A search for environmental factors. *Am J Dis Child* 1986;140:1263–7.
- 67 Hannon WH, Hill RH Jr, Bernert JT Jr, Haddock L, Lebron G, Cordero JF. Premature thelarche in Puerto Rico: a search for environmental estrogenic contamination. *Arch Environ Contam Toxicol* 1987;16:255–62.
- 68 Denham M, Schell LM, Deane G, Gallo MV, Ravenscroft J, DeCaprio AP. Relationship of lead, mercury, mirex, dichlorodiphenyldichloroethylene, hexachlorobenzene, and polychlorinated biphenyls to timing of menarche among Akwesasne Mohawk girls. *Pediatrics* 2005;115:e127–34.
- 69 Blanck HM, Marcus M, Tolbert PE, Rubin C, Henderson AK, Hertzberg VS, et al. Age at menarche and tanner stage in girls exposed in utero and postnatally to polybrominated biphenyl. *Epidemiology* 2000;11:641–7.
- 70 Windham GC, Bottomley C, Birner C, Fenster L. Age at menarche in relation to maternal use of tobacco, alcohol, coffee and tea during pregnancy. *Am J Epidemiol* 2004;159:862–71.
- 71 Ouyang F, Perry MJ, Venners SA, Chen C, Wang B, Yang F et al. Serum DDT, age at menarche, and abnormal menstrual cycle length. *Occup Environ Med* 2005;62:878–4.
- 72 Guillette EA, Conard C, Lares F, Aguilar MG, McLachlan J, Guillette LJ Jr. Altered breast development in young girls from an agricultural environment. *Environ Health Perspect* 2006;114:471–5.
- 73 Krstevska-Konstantinova M, Charlier C, Craen M, Du Caju M, Heinrichs C, de Beaufort C, et al. Sexual precocity after immigration from developing countries to Belgium : evidence of previous exposure to organochlorine pesticides. *Hum Reprod* 2001;16:1020–6.
- 74 Vasiliu O, Muttineni J, Karmaus W. In utero exposure to organochlorines and age at menarche. *Hum Reprod* 2004;19:150612.
- 75 Selevan SG, Rice DC, Hogan KA, Euling SY, Pfahles-Hutchens A, Bethel J. 2003. Blood lead concentration and delayed puberty in girls. *N Engl J Med* 2003;348(16):1527–36.
- 76 Cohn BA, Cirillo PM, Wolff MS, Schwingl PJ, Cohen RD, Sholtz RI, et al. DDT and DDE exposure in mothers and time to pregnancy in daughters. *Lancet* 2003;361:2205–6.

- 77 Venners SA, Korrick S, Xu X, Chen C, Guang W, Huang A, et al. Preconception serum DDT and pregnancy loss: a prospective study using a biomarker of pregnancy. *Am J Epidemiol* 2005;162:709–16.
- 78 Longnecker MP, Klebanoff MA, Dunson DB, Guo X, Chen Z, Zhou H, et al. Maternal serum level of the DDT metabolite DDE in relation to fetal loss in previous pregnancies. *Environ Res* 2005;97:127–33.
- 79 Perez KM, Titus-Ernstoff L, Hatch EE, Troisi R, Wactawski-Wende J, Palmer JR, et al. Reproductive outcomes in men with prenatal exposure to diethylstilbestrol. *Fertil Steril* 2005;84(6):1649–56.
- 80 Palmer JR, Hatch EE, Rao RS, Kaufman RH, Herbst AL, Noller KL, et al. Infertility among women exposed prenatally to diethylstilbestrol. *Am J Epidemiol* 2001;154(4):316–21.
- 81 Hruska KS, Furth PA, Seifer DB, Sharara FI, Flaws JA. Environmental factors in infertility. *Clin Obstet Gynecol* 2000;43:821–9.
- 82 Younglai EV, Holloway AC, Foster WG. Environmental and occupational factors affecting fertility and IVF success. *Hum Reprod Update* 2005;11:43–57.
- 83 Sharara FI, Seifer DB, Flaws JA. Environmental toxicants and female reproduction. *Fertil Steril* 1998;70:613–22.
- 84 Miller KP, Borgeest C, Greenfeld C, Tomic D, Flaws JA. In utero effects of chemicals on reproductive tissues in females. *Toxicol Appl Pharmacol* 2004;198:111–31.
- 85 Toft G, Hagmar L, Giwercman A, Bonde JP. Epidemiological evidence on reproductive effects of persistent organochlorines in humans. *Reprod Toxicol* 2004;19:5–26.
- 86 Jauniaux E, Poston L, Burton GJ. Placental-related diseases of pregnancy: involvement of oxidative stress and implications in human evolution. *Hum Reprod Update* 2006;12:747–55.
- 87 St-Louis J, Brochu M. The cardiovascular paradox of pregnancy. *Med Sci (Paris)* 2007;23:944–9.
- 88 Bricker L, Farquharson RG. Types of pregnancy loss in recurrent miscarriage: implications for research and clinical practice. *Hum Reprod* 2002;17:1345–50.
- 89 Buss L, Tolstrup J, Munk C, Bergholt T, Ottesen B, Gronbaek M, et al. Spontaneous abortion: A prospective cohort study of younger women from the general population in Denmark. Validation, occurrence and risk determinants. *Acta Obstetrica Et Gynecologica Scandinavica* 2006;85:467–75.
- 90 Chard T. Frequency of implantation and early pregnancy loss in natural cycles. *Baillieres Clinical Obstetrics And Gynaecology* 1991;5:179–89.
- 91 Regan L, Rai R. 2000. Epidemiology and the medical causes of miscarriage. *Best Pract Res Clin Obstet Gynaecol* 14(5):839–54.
- 92 Burton G, Hempstock J, Jauniaux E. 2003. Oxygen, early embryonic metabolism and free radical-mediated embryopathies. *Reproductive BioMedicine Online* 6(1):84–96.
- 93 Spinillo A, Iasci A, Capuzzo E, Stronati M, Ometto A, Guaschino S. Early neonatal prognosis in preeclampsia — a matched case-control study in low-birth-weight infants. *Hypertention in Pregnancy* 1993;12(3):507–15.
- 94 Hediger ML, Scholl TO, Schall JI, Miller LW, Fischer RL. Fetal growth and the etiology of preterm delivery. *Obstet Gynecol* 1995;85(2):175–82.
- 95 McCowan LME, George-Haddad M, Stacey T, Thompson JMD. Fetal growth restriction and other risk factors for stillbirth in a New Zealand setting. *Australian New Zealand J Obstet Gynaecol* 2007;47 (6):450–56.
- 96 Battin, MR; McCowan, LME; George-Haddad, M; Thompson JMD. Fetal growth restriction and other factors associated with neonatal death in New Zealand. *Aust N Z J Obstet Gyn* 2007;47(6):457–63.
- 97 Silver, RM. Fetal death. *Obstet Gynecol* 2007;109(1):153–67.
- 98 McCormick MC. The contribution of low birth weight to infant mortality and childhood morbidity. *N Engl J Med* 1985;82:378–82.
- 99 Institute of Medicine (IOM). Preterm birth: causes, consequences, and prevention. Washington, DC: National Academy Press, 2006.
- 100 Windham G, Fenster L. Environmental contaminants and pregnancy outcomes. *Fertil Steril* 2008;89(Suppl 1):e111–e116.
- 101 Pardthaisong T, Gray RH. 1991. In-Utero Exposure to Steroid-Contraceptives and Outcome of Pregnancy. *Am J Epidemiol* 134(8):795–803.
- 102 Longnecker MP, Klebanoff MA, Zhou H, Brock JW. Association between maternal serum concentration of the DDT metabolite DDE and preterm and small-for-gestational-age babies at birth. *Lancet* 2001;358:110–4.
- 103 Bamigboye AA, Morris J. Oestrogen supplementation, mainly diethylstilbestrol, for preventing miscarriages and other adverse pregnancy outcomes. *Cochrane Database Syst Review* 2003;(3):CD004353.
- 104 Derfoul A, Lin FJ, Awumey EM, Kolodzeski T, Hall DJ, Tuan RS. Estrogenic endocrine disruptive components interfere with calcium handling and differentiation of human trophoblast cells. *J Cell Biochem* 2003;89:755–70.
- 105 Richard S, Moslemi S, Sipahutar H, Benachour N, Seralini GE. Differential effects of glyphosate and roundup on human placental cells and aromatase. *Environ Health Perspect* 2005;113:716–20.
- 106 Tachibana T, Wakimoto Y, Nakamura N, Pichitraslip T, Wakitani S, Kusakabe K, Hondo E, Kiso Y. 2007. Effects of bisphenol A (BPA) on placentation and survival of the neonates in mice. *J Reprod Dev* 53(3):509–14.
- 107 Matsuura S, Itakura A, Ohno Y, Nakashima Y, Murata Y, Takeuchi M, et al. Effects of estradiol administration on fetoplacental growth in rat. *Early Hum Dev* 2004;77:47–56.

- 108 Cooper GS, Klebanoff MA, Promislow J, Brock JW, Longnecker MP. Polychlorinated biphenyls and menstrual cycle characteristics. *Epidemiology* 2005;16:191–200.
- 109 Axmon A, Rylander L, Stromberg U, Hagmar L. Altered menstrual cycles in women with a high dietary intake of persistent organochlorine compounds. *Chemosphere* 2004;56:813–9.
- 110 Farr SL, Cooper GS, Cai J, Savitz DA, Sandler DP. Pesticide use and menstrual cycle characteristics among premenopausal women in the Agricultural Health Study. *Am J Epidemiol* 2004;160:1194–204.
- 111 Nikaido Y, Yoshizawa K, Danbara N, Tsujita-Kyutoku M, Yuri T, Uehara N, et al. Effects of maternal xenoestrogen exposure on development of the reproductive tract and mammary gland in female CD-1 mouse offspring. *Reprod Toxicol* 2004;18:803–11.
- 112 Jefferson WN, Padilla-Banks E, Newbold R. Disruption of the female reproductive system by the phytoestrogen genistein. *Reprod Toxicol* 2007;23: 308–316.
- 113 Markey CM, Coombs MA, Sonnenschein C, Soto AM. Mammalian development in a changing environment: exposure to endocrine disruptors reveals the developmental plasticity of steroid-hormone target organs. *Evolution and Development* 2003;5:67–75.
- 114 Rubin BS, Murray MK, Damassa DA, King JC, Soto AM. Perinatal exposure to low doses of bisphenol A affects body weight, patterns of xestrous cyclicity, and plasma LH levels. *Environ Health Perspect* 2001;109:675–680.
- 115 Chao HR, Wang SL, Lin LY, Lee WJ, Papke O. Placental transfer of polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls in Taiwanese mothers in relation to menstrual cycle characteristics. *Food Chem Toxicol* 2007;45:259–65.
- 116 Yang CY, Yu ML, Guo HR, Lai TJ, Hsu CC, Lambert G, et al. The endocrine and reproductive function of the female Yucheng adolescents prenatally exposed to PCBs/PCDFs. *Chemosphere* 2005;61:355–60.
- 117 Franks S, McCarthy MI, Hardy K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. *Int J Androl* 2006;29:278–285.
- 118 Azziz R, Marin C, Hoq L, Badamgarav E, Song P. 2005. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. *J Clin Endocrinol Metab* 2005;90:4650–4658.
- 119 U.S. Department of Health and Human Services, Office on Women's Health. Polycystic Ovarian Syndrome Frequently Asked Questions. www.4woman.gov/FAQ/pcos.htm#a. Viewed August 12, 2008.
- 120 Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. *J Clin Endocrinol Metab* 2004;89:2745–9.
- 121 Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. *J Clin Endocrinol Metab* 1998;83:3078–82.
- 122 Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. *J Clin Endocrinol Metab* 2008;93:162–8.
- 123 Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? *Hum Reprod Update* 2005;11:357–74.
- 124 West C, Foster DL, Evans NP, Robinson J, Padmanabhan V. Intra-follicular activin availability is altered in prenatally-androgenized lambs. *Mol Cell Endocrinol* 2001;185:51–9.
- 125 Forsdike RA, Hardy K, Bull L, Stark J, Webber LJ, Stubbs S, et al. Disordered follicle development in ovaries of prenatally androgenized ewes. *J Endocrinol* 2007;192:421–8.
- 126 Petry CJ, Ong KK, Michelmore KF, Artigas S, Wingate DL, Balen AH, et al. Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women. *Hum Reprod* 2005;20:1837–43.
- 127 Xita N, Tsatsoulis A, Chatzikyriakidou A, Georgiou I. Association of the (TAAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels. *J Clin Endocrinol Metab* 2003;88:5976–80.
- 128 Ikezuki Y, Tsutsumi O, Takai Y, Kamei Y, Taketani Y. Determination of bisphenol A concentrations in human biological fluids reveals significant early prenatal exposure. *Hum Reprod* 2002;17:2839–41.
- 129 Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y, Taketani Y. Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. *Endocr J* 2004;51:165–9.
- 130 Dandekar PV; Martin MC; Glass RH. Polyovular follicles associated with human in vitro fertilization. *Fertil Steril* 1988;49(3):483–86.
- 131 Muretto P, Chilosi M, Rabitti C, Tommasoni S, Colato C. Biovularity and “coalescence of primary follicles” in ovaries with mature teratomas. *Int J Surgical Pathology* 2001;9(2):121–5.
- 132 Kipp JL, Kilen SM, Bristol-Gould S, Woodruff TK, Mayo KE. Neonatal exposure to estrogens suppresses activin expression and signaling in the mouse ovary. *Endocrinology* 2007;148:1968–1976.
- 133 Jefferson WN, Padilla-Banks E, Newbold RR. Adverse effects on female development and reproduction in CD-1 mice following neonatal exposure to the phytoestrogen genistein at environmentally relevant doses. *Biol Reprod* 2005;73:798–806.
- 134 Gougeon A. Frequent occurrence of multi-ovular follicles and multi-nuclear oocytes in the adult human-ovary. *Fertil Steril* 1981;35(4):417–22.
- 135 Sherrer CW, Gerson B; Woodruff JD. Incidence and significance of polynuclear follicles. *Am J Obstet Gynecol* 1977;128(1):6–12.

- 136 Cramer SF, Patel A. The frequency of uterine leiomyomas. *Am J Clin Pathol* 1990;94:435–8.
- 137 Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. *Fertil Steril* 1981;36:433–45.
- 138 Carlson KJ, Miller BA, Fowler FJ Jr. The Maine Women's Health Study: I. Outcomes of hysterectomy. *Obstet Gynecol* 1994;83:556–65.
- 139 Carlson KJ, Miller BA, Fowler FJ Jr. The Maine Women's Health Study: II. Outcomes of nonsurgical management of leiomyomas, abnormal bleeding, and chronic pelvic pain. *Obstet Gynecol* 1994;83:566–72.
- 140 Coronado GD, Marshall LM, Schwartz SM. Complications in pregnancy, labor, and delivery with uterine leiomyomas: a population based study. *Obstet Gynecol* 2000;95:764–9.
- 141 Kjerulff KH, Langenberg P, Seidman JD, Stolley PD, Guzinski GM. Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis. *J Reprod Med* 1996;41:483–90.
- 142 Rice JP, Kay HH, Mahony BS. The clinical significance of uterine leiomyomas in pregnancy. *Am J Obstet Gynecol* 1989;160:1212–6.
- 143 Rowe MK, Kanouse DE, Mittman BS, Bernstein SJ. Quality of life among women undergoing hysterectomies. *Obstet Gynecol* 1999;93:915–21.
- 144 Liu Z, Doan QV, Dubois P, Blumenthal RW. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. *Value in Health* 2007;10(3):183–194.
- 145 Chiaffarino F, Parazzini F, La Vecchia C, Marsico S, Surace M, Ricci E. Use of oral contraceptives and uterine fibroids: results from a case-control study. *Br J Obstet Gynaecol* 1999;106:857–60.
- 146 Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. *Obstet Gynecol* 1997;90:967–73.
- 147 Marshall LM, Spiegelman D, Manson JE, Goldman MB, Barbieri RL, Stampfer MJ, et al. Risk of uterine leiomyomata among premenopausal women in relation to body size and cigarette smoking. *Epidemiology* 1998;9:511–7.
- 148 Parazzini F, Negri E, La Vecchia C, Chatenoud L, Ricci E, Guarnerio P. Reproductive factors and risk of uterine fibroids. *Epidemiology* 1996;7:440–2.
- 149 Kunar RV, Ramakrishna O, Sreeraman PK. Leiomyoma uteri in a bitch. *Can Vet J* 1995;36:185.
- 150 Backlin BM, Eriksson L, Olovsson M. Histology of uterine leiomyoma and occurrence in relation to reproductive activity in the Baltic gray seal (*Halichoerus grypus*). *Vet Pathol* 2003;40:175–80.
- 151 Hodges LC, Hunter DS, Bergerson JS, Fuchs Young R, Walker CL. An in vivo/in vitro model to assess endocrine disrupting activity of xenoestrogens in uterine leiomyoma. *Ann NY Acad Sci* 2001;948:100–11.
- 152 Newbold RR, Jefferson WN, PadillaBanks E. Longterm adverse effects of neonatal exposure to Bisphenol A on the marine female reproductive tract. *Reprod Toxicol* 2007;24(2):253–8.
- 153 Wise LA, Palmer JR, Rowlings K, Kaufman RH, Herbst AL, Noller KL, et al. Risk of benign gynecologic tumors in relation to prenatal diethylstilbestrol exposure. *Obstet Gynecol* 2005;105:167–73.
- 154 Leibson CL, Good AE, Hass SL, Ransom J, Yawn BP, O'Fallon WM et al. Incidence and characterization of diagnosed endometriosis in a geographically defined population. *Fertil Steril* 2004;82:314–21.
- 155 Vigano P, Parazzini F, Somigliana E, Vercellini P. Endometriosis: epidemiology and aetiological factors. *Best Pract Res Clin Obstet Gynaecol* 2004;18:177–200.
- 156 Cramer DW, Missmer SA. The epidemiology of endometriosis. *Ann NY Acad Sci* 2002;955:11–22. discussion 34–6, 396–406.
- 157 Mirkin D, Murphy-Barron C, Iwasaki K. Actuarial analysis of private payer administrative claims data for women with endometriosis. *Journal of Managed Care Pharmacy* 2007;13(3):262–272.
- 158 Simoens S, Hummelshoj L, D'Hooge T. Endometriosis: cost estimates and methodological perspective. *Hum Reprod Update* 2007;13: 395–404.
- 159 Shi YL, Luo XZ, Zhu XY, Hua KQ, Zhu Y, Li DJ. Effects of combined 17betaestradiol with TCDD on secretion of chemokine IL8 and expression of its receptor CXCR1 in endometriotic focus-associated cells in coculture. *Hum Reprod* 2006;21:870–9.
- 160 Rier SE. The potential role of exposure to environmental toxicants in the pathophysiology of endometriosis. *Ann NY Acad Sci* 2002;955:201–12;discussion 30–2, 396–406.
- 161 Rier SE, Martin DC, Bowman RE, Dmowski WP, Becker JL. Endometriosis in rhesus monkeys (*Macaca mulatta*) following chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Fundam Appl Toxicol* 1993;21: 433–41.
- 162 Rier SE, Turner WE, Martin DC, Morris R, Lucier GW, Clark GC. Serum levels of TCDD and dioxin-like chemicals in Rhesus monkeys chronically exposed to dioxin: correlation of increased serum PCB levels with endometriosis. *Toxicol Sci* 2001;59:147–59.
- 163 Cummings AM, Metcalf JL, Birnbaum L. Promotion of endometriosis by 2,3,7,8 tetrachlorodibenzo p dioxin in rats and mice: timedose dependence and species comparison. *Toxicol Appl Pharmacol* 1996;138:131 9.
- 164 Birnbaum LS, Cummings AM. Dioxins and endometriosis: a plausible hypothesis. *Environ Health Perspect* 2002;110:15–21.
- 165 Yang JZ, Agarwal SK, Foster WG. Subchronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin modulates the pathophysiology of endometriosis in the cynomolgus monkey. *Toxicol Sci* 2000;56:374–81.
- 166 Mayani A, Barel S, Soback S, Almagor M. Dioxin concentrations in women with endometriosis. *Hum Reprod* 1997;12:373–5.
- 167 Heilier JF, Nackers F, Verougstraete V, Tonglet R, Lison D, Donnez J. Increased dioxin-like compounds in the serum of women with peritoneal endometriosis and deep endometriotic (adenomyotic) nodules. *Fertil Steril* 2005;84:305–12.

- 168 Cobellis L, Latini G, De Felice C, Razzi S, Paris I, Ruggieri F, et al. High plasma concentrations of di-(2-ethylhexyl)-phthalate in women with endometriosis. *Hum Reprod* 2003;18:1512–5.
- 169 Reddy BS, Rozati R, Reddy BV, Raman NV. Association of phthalate esters with endometriosis in Indian women. *BJOG* 2006;113:515–20.
- 170 Porpora MG, Ingelido AM, di Domenico A, Ferro A, Crobu M, Pallante D, et al. Increased levels of polychlorobiphenyls in Italian women with endometriosis. *Chemosphere* 2006;63:1361–7.
- 171 Hoffman CS, Small CM, Blanck HM, Tolbert P, Rubin C, Marcus M. Endometriosis among women exposed to polybrominated biphenyls. *Ann Epidemiol* 2007;17:503–10.
- 172 Sharara FI, Seifer DB, Flaws JA. Environmental toxicants and female reproduction. *Fertil Steril* 1998;70:613–22.
- 173 Buck Louis GM, Weinter JM, Whitcomb BW, Sperrazza R, Schisterman EF, Lobdell DT, et al. Environmental polychlorinated biphenyl exposure and risk of endometriosis. *Obstet Gynecol Surv* 2005;60:243–4.
- 174 Eskenazi B, Mocarelli P, Warner M, Samuels S, Vercellini P, Olive D, et al. Serum dioxin concentrations and endometriosis: a cohort study in Seveso, Italy. *Environ Health Perspect* 2002;110:629–34.
- 175 Reddy BS, Rozati R, Reddy S, Kodampur S, Reddy P, Reddy R. High plasma concentrations of polychlorinated biphenyls and phthalate esters in women with endometriosis: a prospective case control study. *Fertil Steril* 2006;85:775–9.
- 176 Quaranta MG, Porpora MG, Mattioli B, Giordani L, Libri I, Ingelido AM, et al. Impaired NKcellmediated cytotoxic activity and cytokine production in patients with endometriosis: a possible role for PCBs and DDE. *Life Sci* 2006;79:491–8.
- 177 Missmer SA, Hankinson SE, Spiegelman D, Barbieri RL, Michels KB, Hunter DJ. In utero exposures and the incidence of endometriosis. *Fertil Steril* 2004;82:1501–8.
- 178 Cummings AM, Hedge JM, Birnbaum LS. Effect of prenatal exposure to TCDD on the promotion of endometriotic lesion growth by TCDD in adult female rats and mice. *Toxicol Sci* 1999;52:45–9.
- 179 Koletzko B, Michaelsen K, Hernell O. Short and long term effects of breast feeding on child health. In: *Advances in Experimental Medicine and Biology*. 2002;Vol. 478: Academic Publishers.
- 180 SchackNielsen L, Michaelsen K. Advances in our understanding of the biology of human milk and its effect on the offspring. *J Nutr* 2007;137:503S510S.
- 181 Bonyata, K. 2006. Extended breastfeeding fact sheet. www.kellymom.com/bf/bfextended/ebf-benefits.html#mothers.
- 182 Bonyata, K. 2007. How does milk production work? www.kellymom.com/bf/supply/milkproduction.html.
- 183 Rogan WJ, Gladen BC, McKinney JD, Carreras N, Hardy P, Thullen J, et al. Polychlorinated biphenyls (PCBs) and dichlorodiphenyl dichloroethene (DDE) in human milk: effects on growth, morbidity, and duration of lactation. *Am J Public Health* 1987;77:1294–7.
- 184 Gladen BC, Rogan WJ. DDE and shortened duration of lactation in a northern Mexican town. *Am J Public Health* 1995;85:504 8.
- 185 Karmaus W, Davis S, Fussman C, Brooks K. Maternal concentration of dichlorodiphenyl dichloroethylene (DDE) and initiation and duration of breast feeding. *Paediatr Perinat Epidemiol* 2005;19:388–98.
- 186 Rayner JL, Enoch RR, Fenton SE. Adverse effects of prenatal exposure to atrazine during a critical period of mammary gland growth. *Toxicol Sci* 2005;87:255–66.
- 187 Enoch RR, Stanko JP, Greiner SN, Youngblood GL, Rayner JL, Fenton SE. Mammary gland development as a sensitive end point after acute prenatal exposure to an atrazine metabolite mixture in female Long-Evans rats. *Environ Health Perspect* 2007;115:541–7.
- 188 Gray J. State of the Evidence 2008: The Connection Between Breast Cancer and the Environment. Breast Cancer Fund. 2008. www.breastcancerfund.org/site/pp.asp?c=kwKXLdPaE&b=206137.
- 189 Giusti RM, Iwamoto K, Hatch EE. Diethylstilbestrol revisited: a review of the longterm health effects. *Ann Intern Med* 1995;122:778–88.
- 190 Palmer JR, Wise LA, Hatch EE, Troisi R, TitusErnstoff L, Strohsnitter W, et al. Prenatal diethylstilbestrol exposure and risk of breast cancer. *Cancer Epidemiol Biomarkers Prev* 2006;15:1509–14.
- 191 Troisi R, Hatch EE, Titus Ernstoff L, Hyer M, Palmer JR, Robboy SJ, et al. Cancer risk in women prenatally exposed to diethylstilbestrol. *Int J Cancer* 2007;121:356–60.
- 192 Boylan ES, Calhoon RE. Prenatal exposure to diethylstilbestrol: ovarian-independent growth of mammary tumors induced by 7,12 dimethylbenz[a]anthracene. *J Natl Cancer Inst* 1981;66:649–52.
- 193 Vandenberg LN, Maffini MV, Wadia PR, Sonnenschein C, Rubin BS, Soto AM. Exposure to environmentally relevant doses of the xenoestrogen Bisphenol A alters development of the fetal mouse mammary gland. *Endocrinology* 2007;148:116–27.
- 194 Murray TJ, Maffini MV, Ucci AA, Sonnenschein C, Soto AM. Induction of mammary gland ductal hyperplasias and carcinoma in situ following fetal Bisphenol A exposure. *Reprod Toxicol* 2007;23:383–90.
- 195 Durando M, Kass L, Piva J, Sonnenschein C, Soto AM, Luque EH, et al. Prenatal Bisphenol A exposure induces preneoplastic lesions in the mammary gland in Wistar rats. *Environ Health Perspect* 2007;115:80–6.
- 196 Markey CM, Luque EH, Munoz De Toro M, Sonnenschein C, Soto AM. In utero exposure to Bisphenol A alters the development and tissue organization of the mouse mammary gland. *Biol Reprod* 2001;65:1215–23.
- 197 Martin LJ, Boyd NF. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. *Breast Cancer Res* 2008;10:201.

- 198 Munoz de Toro M, Markey CM, Wadia PR, Luque EH, Rubin BS, Sonnenschein C, et al. Perinatal exposure to Bisphenol A alters peripubertal mammary gland development in mice. *Endocrinology* 2005;146:4138–47.
- 199 Wadia PR, Vandenberg LN, Schaeberle CM, Rubin BS, Sonnenschein C, Soto AM. Perinatal Bisphenol A exposure increases estrogen sensitivity of the mammary gland in diverse mouse strains. *Environ Health Perspect* 2007;115:592–8.
- 200 Lee PN, Hamling J. Environmental tobacco smoke exposure and risk of breast cancer in nonsmoking women: A review with meta analyses. *Inhalation Toxicology* 2006;18:1053–70.
- 201 Reynolds P, Hurley S, Goldberg DE, AntonCulver H, Bernstein L, Deapen D, et al. Active smoking, household passive smoking, and breast cancer: evidence from the California Teachers Study. *Journal of the National Cancer Institute* 2004;96:29–37.
- 202 Band PR, Le ND, Fang R, Deschamps M. Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. *Lancet* 2002;360:1033–4.
- 203 Calle EE, MiracleMcMahill HL, Thun MJ, Heath CW Jr. Cigarette smoking and risk of fatal breast cancer. *Am J Epidemiol* 1994;139(10):1001–7.
- 204 Marcus PM, Newman B, Millikan RC, Moorman PG, Baird DD, Qaqish B. The associations of adolescent cigarette smoking, alcoholic beverage consumption, environmental tobacco smoke, and ionizing radiation with subsequent breast cancer risk (United States). *Cancer Causes and Control* 2000;11(3):271–278.
- 205 Johnson KC, Hu J, Mao Y. Passive and active smoking and breast cancer risk in Canada, 1994–1997, The Canadian Cancer Registries Epidemiology Research Group. *Cancer Causes and Control* 2000;11:211–221.
- 206 Gram IT, Braaten T, Terry PD, Sasco AJ, Adami HO, Lund EE, Weiderpass E. Breast cancer among women who started smoking as teenagers. *Cancer Epidemiology Biomarkers and Prevention* 2005;14:61–66.
- 207 Cohn BA, Wolff MS, Cirillo PM, Sholtz RI. DDT and breast cancer in young women: new data on the significance of age at exposure. *Environ Health Perspect* 2007;115:1406–14.
- 208 Safe S, Papineni S. The role of xenoestrogenic compounds in the development of breast cancer. *Trends Pharmacol Sci* 2006;27:447–54.
- 209 McElroy JA, Gangnon RE, Newcomb PA, Kanarek MS, Anderson HA, Brook JV, et al. Risk of breast cancer for women living in rural areas from adult exposure to atrazine from well water in Wisconsin. *J Expo Sci Environ Epidemiol* 2007;17:207–14.
- 210 Rudel RA, Attfield KR, Schifano JN, Brody JG. Chemicals causing mammary gland tumors in animals signal new directions for epidemiology, chemicals testing, and risk assessment for breast cancer prevention. *Cancer* 2007;109:2635–66.
- 211 Sinha P, Kuruba N. Premature ovarian failure. *J Obstet Gynaecol* 2007;27:16–9.
- 212 Goswami D, Conway GS. Premature ovarian failure. *Hormone Research* 2007;68:196–202.
- 213 McGee EA, Hsueh AJ. Initial and cyclic recruitment of ovarian follicles. *Endocr Rev* 2000;21:200–14.
- 214 Nippita TA, Baber RJ. Premature ovarian failure: a review. *Climacteric* 2007;10(1):11–22.
- 215 Matikainen T, Perez GI, Jurisicova A, Pru JK, Schlezinger JJ, Ryu HY, et al. Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environmental chemicals. *Nature Genetics* 2001;28: 355–360.
- 216 Sir-Petermann T, Hittsfield C, Maliqueo M, Codner E, Echiburu B, Gazitua R, et al. Birth weight in offspring of mothers with polycystic ovarian syndrome. *Hum Reprod* 2005;20:2122–6.
- 217 Dulloo AG, Jacquet J, Seydoux J, Montani JP. The thrifty ‘catch-up fat’ phenotype: its impact on insulin sensitivity during growth trajectories to obesity and metabolic syndrome. *Int J Obes* 2006;30:S23–35.
- 218 Amador-Licona N, Martinez-Cordero C, Guizar-Mendoza JM, Malacara JM, Hernandez J, Alcalá JF. Catch-up growth in infants born small for gestational age — a longitudinal study. *J Pediatr Endocrinol Metab* 2007;20:379–86.
- 219 Cripps RL, Martin-Gronert MS, Ozanne SE. Fetal and perinatal programming of appetite. *Clin Sci* 2005;109:1–11.
- 220 Weaver LT. Rapid growth in infancy: balancing the interests of the child. *J Pediatr Gastroenterol Nutr* 2006;43:428–32.
- 221 Veening MA, van Weissenbruch MM, Roord JJ, Delemarre-van de Waal HA. Pubertal development in children born small for gestational age. *J Pediatr Endocrinol Metab* 2004;17:1497–505.



This report summarizes the key outcomes of the Women's Reproductive Health and the Environment Workshop. The workshop was convened by the Collaborative on Health and the Environment (CHE), in partnership with the University of Florida (UF) and the University of California, San Francisco's Program on Reproductive Health and the Environment (PRHE). This event was co-chaired by Dr. Louis Guillette at UF (www.zoology.ufl.edu/ljg) and Dr. Linda Giudice at PRHE (www.prhe.ucsf.edu). Please contact these individuals for further information about this research.



For more information about the workshop and to download copies of this report, please visit www.healthandenvironment.org/reprohealthworkshop.

This report was produced by the Collaborative on Health and the Environment. CHE's administrative headquarters are located at Commonweal, a health and environmental research institute in Bolinas, California.

For hard copies of this report or for more information, please contact:

CHE/Commonweal
PO Box 316, Bolinas, CA 94924
Telephone: 415-868-0970
Fax: 415-868-2230
Email: info@healthandenvironment.org
Web: www.healthandenvironment.org

Printed with soy-based ink on New Leaf Reincarnation paper
(100% recycled, 50% post-consumer content, processed chlorine free).

Design by half-full (www.half-full.org)